Document:

EX-10.24

 

Exhibit 10.24

CONFIDENTIAL
MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

Amendment

BTG, Duke and MVP agree as follows:

Article 1 — Definitions

	1.0	 	Unless specifically defined in this Amendment, the capitalized terms shall have the meanings
ascribed to them in the Agreement.

	1.1	 	“Agreement” shall mean the License Agreement entered into by and among BTG, Duke and MVP on
August 12, 1998.

	1.2	 	“Amendment” shall mean this amendment to the Agreement entered into by and among BTG, Duke
and MVP as of the Amendment Date.

	1.3	 	“Amendment Date” shall mean November 12, 2001.

Article 2 — Amendments

	3.0	 	Effective as of the Amendment Date, the Agreement is amended to delete Section 9.1(b) in its
entirety.

	3.1	 	This amendment is conditioned upon the payment to MVP by BTG (by wire transfer) of $[**],
(consisting of $[**] allocated to Milestone No. 4 and $[**] allocated to Milestone No.
5), as an advance payment in partial satisfaction of the payments due under Milestone Nos.
4 and 5.

	3.2	 	BTG shall provide to MVP complete copies of all written and electronic communications related
to PEG-uricase, such as regulatory filings and other correspondence, to and from government
regulatory agencies (including, without limitation, the U.S. Food and Drug Administration),
within five (5) business days of BTG’s filing or receipt, respectively, of such
communications.

Article 3 — Miscellaneous

	3.1	 	This Amendment shall be effective as of the Amendment Date.

	3.2	 	Except as expressly modified in this Amendment, the Agreement shall remain in full force and
effect according to its terms.

IN WITNESS WHEREOF, BTG, Duke and MVP have caused this Amendment to be executed as of the Amendment
Date by their duly authorized officers.

	 	 	 	 	 
	 	BlO-TECHNOLOGY GENERAL CORP.

 	 
	 	By:  	/s/ Norman Barton
 	 
	 	 	Name:  	Norman Barton 	 
	 	 	Title:  	Chief Medical Officer 	 
	 

	 	 	 	 	 
	 	DUKE UNIVERSITY

 	 
	 	By:  	/s/ Robert L. Taber
 	 
	 	 	Name:  	Robert L. Taber, Ph.D. 	 
	 	 	Title:  	Vice Chancellor. Science & Tech. Dev. 	 
	 

	 	 	 	 	 
	 	MOUNTAIN VIEW PHARMACEUTICALS, INC.

 	 
	 	By:  	/s/ Mark Saifer
 	 
	 	 	Name:  	Mark Saifer 	 
	 	 	Title:  Vice President	 
	 

 

 

LICENSE AGREEMENT

     THIS LICENSE AGREEMENT is made and entered into as of the 12th day of August 1998,
by and among Mountain View Pharmaceuticals, Inc., Duke University, and Bio-Technology General
Corporation.

     WHEREAS, DUKE has developed certain recombinant mammalian uricases prior to the start of the
GRANT, including PBC URICASE;

     WHEREAS, DUKE and/or MVP have developed, pursuant to the GRANT, additional recombinant
mammalian uricases;

     WHEREAS, DUKE and MVP have developed, pursuant to the GRANT, PEG conjugates of PBC URICASE and
other mammalian uricases;

     WHEREAS, MVP has developed PEG conjugates of non-mammalian uricases;

     WHEREAS, DUKE and MVP, in order to have the benefits of these developments made available to
the public, desire to license their rights therein exclusively, on a worldwide basis, to BTG in the
FIELD; and

     WHEREAS, BTG desires to obtain such a license.

     NOW THEREFORE, in consideration of the premises and the faithful performance of the covenants
herein contained, the PARTIES agree as follows:

ARTICLE
1 — INDEPENDENT CONTRACTORS

	1.0	 	MVP’s and DUKE’s relationships to one another and to BTG under this AGREEMENT are those of
independent contractors and not as agents, joint venturers or partners.

ARTICLE
2 — DEFINITIONS

	2.0	 	As used throughout this AGREEMENT, the terms and phrases set forth herein in capital letters
shall be defined as set forth in this Article 2.

	2.1	 	“AFFILIATES” of a person or an entity shall mean any individual, sole proprietorship, firm,
partnership, corporation, trust, joint venture or other entity, whether de jure or de facto,
which, directly or indirectly, controls, is controlled by or is under common control with such
person or entity. As used in this definition, “control” means the possession, directly or
indirectly, of the power to direct or cause the direction of the policies and management of a
person or entity, whether by the ownership of stock, by contract or otherwise.

	2.2	 	“AGREEMENT” shall mean this License Agreement as amended from time to time.

	2.3	 	“BIRD” shall mean the U.S.-Israel Binational Industrial Research and Development Foundation.

	2.4	 	“BTG” shall mean Bio-Technology General Corporation, a corporation organized under the laws
of Delaware, and having its principal offices at Iselin, New Jersey 08830, and its AFFILIATES.

	2.5	 	“DUKE” shall mean Duke University, a North Carolina not-for-profit corporation, having its
principal office at Durham, North Carolina 27710, and its AFFILIATES.

 

 

	2.6	 	“DUKE TECHNOLOGY” shall mean technologies conceived, reduced to practice, developed, or
acquired, by or for DUKE, or licensed to DUKE, or developed jointly with MVP, relating to
mammalian urate oxidase (mammalian uricase), including the know-how and other information
described in detail in Exhibit A attached hereto and made a part hereof, as of the EFFECT1VE
DATE, and including any improvement made by DUKE thereon during the TERM of this AGREEMENT,
for use in the FIELD; provided, however, that with respect to such improvements DUKE shall
promptly disclose each such improvement to BTG and it shall be included in the license only
if, within six (6) months after disclosure, BTG elects to incorporate the improvement into
LICENSED PRODUCTS or the manufacturing process thereof.

	2.7	 	“EFFECTIVE DATE” shall mean the date first written above.

	2.8	 	“FIELD” shall mean the treatment of humans.

	2.9	 	“GRANT” shall mean the STTR grant from NIH (Grant No. DK48529) for a research project titled,
“Mammalian PEG-Uricase for Therapy of Intractable Gout” under which LICENSORS received funding
from September 30, 1996, through August 31, 1998.

	2.10	 	“IMPUTED NET SALES” shall have the meaning ascribed to it in Section 2.17(a).

	2.11	 	“INFORMATION” shall have the meaning ascribed to it in Section 11.1.

	2.12	 	“LICENSED PRODUCTS” shall mean any products (including all dosage forms, strengths, and
package sizes) that utilize TECHNOLOGY in whole or in part.

	2.13	 	“LICENSEE” shall mean BTG.

	2.14	 	“LICENSOR” shall mean MVP, DUKE or both of them, depending on the context.

	2.15	 	“MVP” shall mean Mountain View Pharmaceuticals, Inc., a corporation organized under the laws
of California, and having its principal place of business at Menlo Park, California 94025, and
its AFFILIATES.

	2.16	 	“MVP TECHNOLOGY” shall mean technologies conceived, reduced to practice, developed, or
acquired, by or for MVP, or licensed to MVP, or developed jointly with DUKE, relating to
mammalian urate oxidase (mammalian uricase) and non- mammalian urate oxidase (non-mammalian
uricase) and PEG conjugates of both mammalian uricase and non-mammalian uricase, including the
know-how and other information described in detail in Exhibit B attached hereto and made a
part hereof, as of the EFFECTIVE DATE, including any improvements made by MVP thereon during
the TERM of this AGREEMENT, for use in the FIELD; provided, however, that with respect to such
improvements, MVP shall promptly disclose each such improvement to BTG and it shall be
included in the license only if, within six (6) months after disclosure, BTG elects to
incorporate the improvement into LICENSED PRODUCTS or the manufacturing process thereof.

	2.17	 	“NET SALES” shall mean LICENSEE’s aggregate arm’s length gross charges to the trade,
physicians or patients charged for sales by LICENSEE of the LICENSED PRODUCTS, less all normal
and customary trade and quantity discounts and less any sales and excise taxes and duties paid
by LICENSEE.

	 	(a)	 	In the event that the LICENSED PRODUCTS are distributed by LICENSEE at no cost
to the recipient for revenue-producing activities, these shall be deemed to be NET
SALES (“IMPUTED NET SALES”) for purposes of computing royalty

 

 

	 	 	 	obligations, except for LICENSED PRODUCTS distributed that are not reimbursable or
which are used for non-revenue- producing activities such as promotional samples and
supplies for clinical studies or field trials.
	 
	 	(b)	 	IMPUTED NET SALES shall be valued at the mean price for such respective
LICENSED PRODUCTS sold by LICENSEE during the calendar quarter preceding the calendar
quarter during which such IMPUTED NET SALES occur.
	 
	 	(c)	 	Transfer prices for LICENSED PRODUCTS between AFFILIATES shall not be
considered for the purpose of computing NET SALES or IMPUTED NET SALES.

	2.18	 	“NIH” shall mean the US. National Institutes of Health.
	 
	2.19	 	“PATENT RIGHTS” shall mean rights to any claims directed to any aspect of the TECHNOLOGY in
all United States and foreign patent applications filed and any patents now issued or
hereinafter issuing from such patent applications, substitutes, continuations,
continuations-in-part, divisional applications, reexaminations or reissues thereof, which
contain at least one claim directed to any aspect of the TECHNOLOGY, a current listing of
which appears in Exhibit C attached hereto and made a part hereof, as amended from time to
time during the TERM of this AGREEMENT.
	 
	2.20	 	“PARTY” or “PARTIES” shall mean LICENSEE on the one hand and DUKE and/or MVP on the other
hand, or all three, depending on the context.
	 
	2.21	 	“PBC URICASE” shall mean [**].
	 
	2.22	 	“PEG” shall mean poly(ethylene glycol) or poly(ethylene oxide).
	 
	2.23	 	“SALES AND REVENUE REPORTS” shall have the meaning ascribed to it in Section 6.9.
	 
	2.24	 	“STTR” shall mean the Small Business Technology Transfer Research program.
	 
	2.25	 	“SUBLICENSE REVENUES” shall mean all revenues or other consideration received by LICENSEE
from sublicensees, including, without limitation, sublicense issue fees, other sublicense
fees, royalties, and milestone payments.
	 
	2.26	 	“TECHNOLOGY” shall mean the DUKE TECHNOLOGY and the MVP TECHNOLOGY.
	 
	2.27	 	“TERM” shall have the meaning ascribed to it in Section 10.1.
	 
	2.28	 	“TERRITORY” shall mean each and every country of the world, including, with respect to each
country, its territories and possessions.
	 
	2.29	 	“TOP [**] MARKETS” shall mean the [**] countries with the greatest dollar volume of sales of
allopurinol during the twelve (12) months preceding any particular date, based on monthly data
compiled by IMS America.
	 
	2.30	 	“TOTAL REVENUES” shall mean the sum of NET SALES plus SUBLICENSE REVENUES.
	 
	2.31	 	“TOTAL SALES” shall mean the cumulative sum of NET SALES of LICENSED PRODUCTS by LICENSEE
plus net sales of LICENSED PRODUCTS by its sublicensees from the EFFECTIVE DATE.
	 
	2.32	 	“USPTO” shall mean the United States Patent and Trademark Office.

 

 

ARTICLE
3 — SPONSORED RESEARCH

	3.1	 	LICENSEE shall sponsor research relevant to the TECHNOLOGY at the facilities of each of the
LICENSORS.

	3.2	 	LICENSEE agrees to provide not less than $[**] to DUKE and $[**] to MVP (less any amounts
received by MVP from BIRD) for sponsored research during the first twenty-four (24) months
following the EFFECTIVE DATE.

	3.3	 	Payments for such sponsored research shall be made at least semiannually to each of the
LICENSORS at the annual rate of at least $[**] per year; provided, however, that with respect
to MVP, these payments shall be reduced by the amounts received by MVP from BIRD.

	3.4	 	The funding for sponsored research at DUKE is to support research at DUKE by Dr. [**], and it
is understood that if for any reason, Dr. [**] should no longer be affiliated with DUKE during
the period for which the funding is provided, then DUKE will transfer the funding to another
institution with which Dr. [**] may affiliate, upon his departure from DUKE.

ARTICLE
4 — LICENSE AND TRANSFER OF TECHNOLOGY

	4.1	 	LICENSORS hereby grant to LICENSEE and LICENSEE hereby accepts from LICENSORS, upon the terms
and conditions herein specified, an exclusive, royalty-bearing license in the TERRITORY, with
the right to grant sublicenses, under the TECHNOLOGY and PATENT RIGHTS, subject to U.S.
Government rights in the TECHNOLOGY, to make and have made, use and have used, and sell and
have sold, LICENSED PRODUCTS for use in the FIELD. In recognition of the general applicability
to other drugs of MVP’s technology for the production of PEG conjugates of uricases, BTG
expressly agrees that it shall not utilize such technology in any manner except for the
production of PEG conjugates of uricases and only as provided in this AGREEMENT; provided,
however, that MVP expressly agrees that nothing contained in this AGREEMENT shall be read to
preclude LICENSEE from using technology for the production of PEG conjugates which is in the
public domain, or which is developed by LICENSEE independent of MVP’s technology for the
production of PEG conjugates, or which LICENSEE acquires or licenses from a third party.

	4.2	 	Within sixty (60) days after the execution of this AGREEMENT:

	 	(a)	 	DUKE agrees to provide LICENSEE with the materials and copies of the protocols
and representative results for the methods listed in Exhibit A.
	 
	 	(b)	 	MVP agrees to provide LICENSEE with the materials and copies of the protocols
and representative results for the methods listed in Exhibit B.
	 
	 	(c)	 	LICENSORS agree to provide LICENSEE with copies of any and all patents and
patent applications identified in Exhibit C.

	4.3	 	MVP hereby grants to LICENSEE the exclusive, royalty-free, right and license in the TERRITORY
and in the FIELD to use such rights as MVP may possess in the trademark, PURICASETM, the
registration of which has been published in the Official Gazette of the USPTO (Volume 1211,
Number 2, page TM 100) and is pending in the European Community (Application No. 716019).

 

 

	 	(a)	 	LICENSEE may use whichever trademark or trademarks it may elect, in its sole
discretion, in connection with the marketing of LICENSED PRODUCTS, and shall be under
no obligation to use the trademark, PURICASETM.
	 
	 	(b)	 	If LICENSEE elects not to use the trademark PURICASETM or otherwise
fails to use such trademark by one (1) year after the first sale of any LICENSED
PRODUCT, MVP shall retain all rights to its use.

	4.4	 	LICENSEE shall comply with all obligations imposed by the U.S. Government on exclusive
licenses of inventions made under a U.S. Government funding agreement including, but not
limited to, the requirement that any products which are sold in the United States be
substantially manufactured in the United States, if such products are based on inventions
conceived or first actually reduced to practice under such funding agreements.

	 	(a)	 	LICENSORS recognize that the currently projected market for LICENSED PRODUCTS
does not justify a second manufacturing facility, and that LICENSEE currently has a
manufacturing facility in Israel, and, therefore, LICENSORS and LICENSEE agree to
cooperate and use their best efforts to promptly obtain a waiver of the U.S.
manufacturing requirement.
	 
	 	(b)	 	DUKE represents that PBC URICASE was constructed at DUKE prior to its receipt
of the GRANT and that U.S. Government funds did not support its development; and
represents further that subject to review and determination by DUKE, other uricases may
also have been constructed at DUKE prior to its receipt of the GRANT, developed without
the support of U.S. Government funds, and that DUKE shall promptly identify any such
uricases for LICENSEE.

	4.5	 	Any sublicenses granted by LICENSEE shall be on such financial terms as LICENSEE may
negotiate in its sole discretion but otherwise shall be subject to, and shall incorporate
therein, conditions at least as stringent as those imposed on LICENSEE by the terms of this
AGREEMENT.

	 	(a)	 	LICENSEE agrees to be responsible for any obligations assumed hereunder by its
sublicensees.
	 
	 	(b)	 	LICENSEE further agrees that all sublicense agreements will provide that if
LICENSORS terminate this AGREEMENT pursuant to Section 10.3 or 10.6 prior to the end of
the TERM in one or more countries, or if LICENSEE terminates this AGREEMENT pursuant to
Section 10.2, all such sublicenses in those countries shall be assigned directly to
LICENSORS; provided, however, that LICENSORS first agree, in writing, to assume all of
LICENSEE’s obligations under such sublicenses and to hold LICENSEE harmless with
respect to any claims made by such sublicensees as a result of such termination;
provided, however, that LICENSORS shall not be liable for any claims against LICENSEE
arising out of LICENSEE’s negligence or willful wrongdoing, or claims arising from
LICENSEE’s breach, prior to termination, of its obligations under a sublicense.
	 
	 	(c)	 	LICENSORS shall promptly be provided a copy of each sublicense agreement,
provided, however, that during the TERM of this AGREEMENT, LICENSORS shall maintain
such agreements in confidence and shall not contact any such sublicensee without
LICENSEE’s prior written consent.

 

 

	4.6	 	Upon expiration of the TERM of this AGREEMENT with respect to each country as set forth in
Article 10, the licenses granted in this Article 4 shall become fully paid-up, irrevocable and
non-exclusive in each such country.

ARTICLE
5 — LICENSE FEES AND MILESTONE PAYMENTS

	5.1.	 	The LICENSEE shall make separate payments to MVP and to DUKE according to the following
schedule:

	 	 	 	 	 	 	 
	 	 	[**] of U.S. Dollars
	Event Triggering Payments	 	To MVP	 	To DUKE	 	Total
	1) Execution of this AGREEMENT
	 	[**]	 	[**]	 	[**]
	2) Successful transfer of the technology for the production of
PEG conjugates of uricase
	 	[**]	 	[**]	 	[**]
	3) First anniversary of execution of this AGREEMENT
	 	[**]	 	[**]	 	[**]
	4) Filing for an investigational new drug exemption
	 	[**]	 	[**]	 	[**]
	5) Commencement of a Phase 2 clinical study
	 	[**]	 	[**]	 	[**]
	6) Filing of an application to permit marketing in any one of the
[**]
	 	[**]	 	[**]	 	[**]
	7) Marketing approval in any one of the [**]
	 	 	 	[**]	 	[**]
	8) Cumulative TOTAL REVENUES of $[**]
	 	[**]	 	[**]	 	[**]
	9) Cumulative TOTAL REVENUES of $[**]
	 	[**]	 	[**]	 	[**]
	Totals:
	 	[**]	 	[**]	 	[**]

	5.2	 	LICENSEE shall make the payments identified in Section 5.1 as follows:

	 	(a)	 	Payments 1) upon execution of this AGREEMENT.
	 
	 	(b)	 	Payments 2) not later than thirty (30) days after successful transfer of the
technology for the production of PEG conjugates of uricase, as set forth in Section
5.10.
	 
	 	(c)	 	Payment 3) on the first anniversary of the EFFECTIVE DATE.
	 
	 	(d)	 	Payments 4) not later than thirty (30) days after the first filing of an
application for an investigational new drug exemption for LICENSED PRODUCTS.
	 
	 	(e)	 	Payments 5) not later than thirty (30) days after enrolling the first patient
in a Phase 2 clinical study of LICENSED PRODUCTS.
	 
	 	(f)	 	Payments 6) not later than thirty (30) days after filing an application to
permit marketing of LICENSED PRODUCTS in any one of the [**].
	 
	 	(g)	 	Payments 7) not later than thirty (30) days after obtaining approval to market
LICENSED PRODUCTS in any one of the [**].
	 
	 	(h)	 	Payments 8) not later than sixty (60) days after the end of the calendar
quarter in which cumulative TOTAL REVENUES from LICENSED PRODUCTS exceed the equivalent
of $[**].
	 
	 	(i)	 	Payments 9) not later than sixty (60) days after the end of the calendar
quarter in which cumulative TOTAL REVENUES from LICENSED PRODUCTS exceed the equivalent
of $[**].

	5.3	 	All of the payments in this Article 5 are in addition to the royalties specified in Article
6.

	5.4	 	All payments required by this AGREEMENT, if not paid when due, shall bear interest at the
rate of one and one-half percent (1
1/2
%) per month or fraction thereof, or the maximum interest
rate allowed by applicable law, whichever is less.

	5.5	 	If this AGREEMENT is executed before LICENSEE has had the opportunity to review and approve
the version of the patent application (titled “PEG-URATE OXIDASE CONJUGATES AND USE THEREOF”)
that has been filed with the United States Patent and Trademark Office, then:

	 	(a)	 	If upon such review subsequent to execution of this AGREEMENT, which LICENSEE
shall complete within sixty (60) days after receipt of such application, LICENSEE
determines in good faith that such application is inadequate (e.g., for lack of support
in the specification or in view of the prior art), LICENSEE may elect, in its sole
discretion, to terminate this AGREEMENT.
	 
	 	(b)	 	If LICENSEE does so elect to terminate, MVP and DUKE shall each refund to
LICENSEE all payments made to them by LICENSEE as of the date of termination, and MVP
shall be solely responsible for the repayment to BIRD, should such repayment be
required, of any funds received by MVP from BIRD.

	5.6	 	MVP shall commence the transfer to BTG of its proprietary
technology for the production of
PEG conjugates of uricases once the following conditions have been met:

	 	(a)	 	MVP and DUKE have been notified, in writing, by BTG following the review of
their patent application as set forth in Section 5.5, either that such patent
application is acceptable or, if unacceptable, that BTG nonetheless elects not to
terminate the AGREEMENT, and that, therefore, the payments made by BTG to MVP and DUKE
as of the date of such written notice are irrevocable;
	 
	 	(b)	 	BTG and MVP have selected a specific uricase and BTG has provided at least [**]
from a single batch to MVP for each [**] of PEG conjugate to be prepared by MVP as part
of the technology transfer; and
	 
	 	(c)	 	BTG has installed at its facility in Israel all of the necessary instruments,
accessories, columns and other materials for assessing the activity of uricase, the
purity of the PEG-uricase conjugates and the number of strands of PEG attached per
uricase subunit according to MVP’s protocols. [**]

 

 

	5.7	 	Such transfer shall commence as soon as practical after BTG has met all of the conditions in
Section 5.6.
	 
	5.8	 	The technology transfer shall include the following steps: [**]
	 
	5.9	 	BTG and MVP shall use their best efforts to complete successful transfer of such technology
as promptly as possible and each company shall therefore assign appropriately skilled
personnel to this task.
	 
	5.10	 	The technology transfer shall be complete once Sections 5.8(c) and 5.8(d) have been completed
and BTG shall notify LICENSORS in writing within thirty (30) days of such completion.
	 
	5.11	 	Failure to successfully transfer the technology within one (1) year after the transfer is
initiated by MVP, unless such failure is caused by BTG’s failing to comply with Section 5.9,
shall have the following consequences:

	 	(a)	 	MVP and DUKE shall forfeit payments 2) in Section 5.1 and they shall not be
made pursuant to Section 5.2 or otherwise; and
	 
	 	(b)	 	MVP and DUKE shall forfeit the royalties attributable to know-how pursuant to
Section 6.4 as further defined in Section 6.5.

	5.12	 	If the U.S. Government declines to waive the U.S. manufacturing requirement, MVP shall
cooperate with LICENSEE to transfer such technology to a U.S. manufacturer selected by
LICENSEE; provided, however:

	 	(a)	 	that payments 2) in Section 5.1 shall have been made;
	 
	 	(b)	 	that such manufacturer shall first agree to maintain such technology in
confidence on terms no less restrictive than those applicable to LICENSEE under this
AGREEMENT, and to use such technology only for the production of PEG-uricase conjugates
for LICENSEE;
	 
	 	(c)	 	that such manufacturer does not manufacture PEG-unease conjugates for itself or
any third party;
	 
	 	(d)	 	that such manufacturer is not [xx], or [xx]; and
	 
	 	(e)	 	that such manufacturer is a company for which, as of the effective date of the
agreement between LICENSEE and such company, none of the following three (3)
individuals: [xx], is
an employee, director, consultant, or shareholder possessing at least ten percent of
the outstanding shares of common stock, unless MVP’s prior written consent has been
obtained, which consent shall not be unreasonably withheld.

ARTICLE
6 — ROYALTIES, RECORDS AND REPORTS

	6.1	 	Within sixty (60) days after the end of each calendar quarter, LICENSEE shall pay to
LICENSORS, in equal shares, any running royalties due pursuant to this Article 6 on NET SALES
of LICENSED PRODUCTS made by LICENSEE during the preceding calendar quarter.

	6.2	 	The total rates of such running royalties, subject to adjustment pursuant to Section
6.5, shall be:

	 	(a)	 	[**] percent ([**] %) of the NET SALES of LICENSED PRODUCTS
made by LICENSEE until the TOTAL SALES equal $[**];
	 
	 	(b)	 	[**] percent ([**] %) of NET SALES of LICENSED PRODUCTS made
by LICENSEE once the TOTAL SALES exceed $[**] and until such TOTAL
SALES equal $[**]; and
	 
	 	(c)	 	[**] percent ([**] %) of NET SALES of LICENSED PRODUCTS made by
LICENSEE once the TOTAL SALES exceed $[**].

	6.3	 	Concurrent with the payments provided for in Sections 6.1 and 6.2 and subject to Sections 6.5
and 6.6, LICENSEE shall pay to LICENSORS, in United States Dollars,

 

 

	 	 	royalty payments in the amount of [**] percent
([**]%) of SUBLICENSE REVENUES accrued by LICENSEE during the
preceding calendar quarter.
	 
	6.4	 	Of the percentages specified in Sections 6.2 and 6.3, one half (1/2) shall be considered a
patent royalty, and one half (1/2) shall be considered a royalty for use of know-how.
	 
	6.5	 	Subject to Article 8, the actual royalty rates payable in any country pursuant to Sections
6.1, 6.2 and 6.3 shall be determined as follows:

	 	(a)	 	If there is no patent protection under PATENT RIGHTS in a country in the
TERRITORY and no protection under the U.S. Orphan Drug Act or any foreign equivalent in
such country, then the applicable royalty rates for such country
shall be [**] percent
([**]%) of the royalty rates specified in Sections 6.2 and 6.3 if there has been a
successful transfer of technology pursuant to Section 5.10, and
[**] percent
([**]%) if
there has not been a successful transfer.
	 
	 	(b)	 	If there is patent protection under PATENT RIGHTS in a country in the TERRITORY
or protection under the U.S. Orphan Drug Act or any foreign equivalent in such country,
then the applicable royalty rates for such country shall be the royalty rates specified
in Section 6.2 and 6.3 if there has been a successful transfer of technology pursuant
to Section 5.10, and [**] percent
([**]%) of the royalty rates specified in Sections 6.2
and 6.3 if there has not been a successful transfer.

	6.6	 	For the purpose of calculating royalties due to LICENSORS, revenues in currencies other than
United States Dollars shall be converted to United States Dollars using the exchange rates
that were published in the Wall Street Journal on the last business day of the calendar
quarter during which LICENSEE accrued such revenues.
	 
	6.7	 	LICENSEE shall keep full, true and accurate books of accounts and other records containing
all particulars that may be necessary to properly ascertain and verify the royalties payable
by LICENSEE hereunder.
	 
	6.8	 	Upon the request of LICENSORS, LICENSEE shall permit an independent Certified Public
Accountant selected by LICENSORS (except one to whom the LICENSEE has some reasonable
objection, such as that the accountant represents either of LICENSORS with respect to its own
matters) to have access, not more than once in any calendar year, and during ordinary business
hours, to such of LICENSEE’ s records as may be necessary to determine, in respect of any
quarter ending not more than three (3) years prior to the date of such request, the
correctness of any report and/or payment made under this AGREEMENT.

	 	(a)	 	If such examination results in a determination that LICENSEE has underpaid its
obligations to LICENSORS by more than three percent (3%), the cost of such examination
shall be borne by LICENSEE.
	 
	 	(b)	 	If such examination results in a determination that LICENSEE has correctly paid
or overpaid its obligations to LICENSORS, the cost of such examination shall be borne
by LICENSORS.
	 
	 	(c)	 	All adjustments resulting from such examinations shall be made by appropriate
payments within thirty (30) days after the results of the examination become known to
the PARTIES.
	 
	 	(d)	 	Such accountant shall maintain all information learned during such inspection
in confidence and shall report to LICENSORS whether there has been an

 

 

overpayment, correct payment or underpayment of royalties and, if applicable, the
amount of such overpayment or underpayment.

	6.9	 	For each quarterly payment, LICENSEE shall render to each of the LICENSORS written accounts
(“SALES AND REVENUE REPORTS”) of the NET SALES of LICENSED PRODUCTS by LICENSEE and
AFFILIATES, net sales by SUBLICENSEES, and the SUBLICENSE REVENUES accrued by LICENSEE during
the preceding quarter.

	 	(a)	 	LICENSEE warrants that such SALES AND REVENUE REPORTS will be prepared in
accordance with Generally Accepted Accounting Principles.
	 
	 	(b)	 	SALES AND REVENUE REPORTS will be supplied to each of the LICENSORS not later
than sixty (60) days after the end of each calendar quarter in which the LICENSEE
accrues revenue from sales of LICENSED PRODUCTS or from sublicenses of the LICENSED
PRODUCTS.
	 
	 	(c)	 	LICENSORS agree to hold such SALES AND REVENUE REPORTS in confidence.

ARTICLE
7 — PERFORMANCE OBLIGATIONS

	7.1	 	The LICENSEE shall use its best efforts to bring LICENSED PRODUCTS to market and to
diligently market LICENSED PRODUCTS during the TERM of this AGREEMENT.

	7.2	 	LICENSEE and MVP shall commit such funds as each may receive from BIRD solely to the
development of LICENSED PRODUCTS.

	7.3	 	LICENSEE shall repay all finds provided by BIRD to LICENSEE
and MVP, up to [**] percent
([**]%) of the grant, as required by BIRD.

	7.4	 	Beginning in 1999 (for calendar year 1998), and continuing until the year following the year
of the first commercial sale of LICENSED PRODUCTS, the LICENSEE shall submit annual progress
reports to LICENSORS by February 28th of each year, which reports shall discuss the progress
and results, as well as ongoing plans, with respect to the development of LICENSED PRODUCTS.

ARTICLE
8 — PATENTS AND INFRINGEMENT

	8.1	 	Subsequent to the EFFECTIVE DATE, LICENSORS shall continue to have responsibility, at their
shared expense, for filing, prosecuting and maintaining their jointly owned patent
applications in the USPTO on TECHNOLOGY; DUKE shall continue to have responsibility, at its
own expense, for filing, prosecuting and maintaining its solely owned patent applications in
the USPTO on DUKE TECHNOLOGY; and MVP shall continue to have responsibility, at its own
expense, for filing, prosecuting and maintaining its solely owned patent applications in the
USPTO on MVP TECHNOLOGY. LICENSORS shall keep LICENSEE advised as to the prosecution of such
applications by forwarding to LICENSEE copies of all official correspondence relating thereto,
and shall give LICENSEE an opportunity to comment on all applications, responses to Office
Actions, Declarations and other papers before they are filed with the USPTO, and shall consult
with LICENSEE concerning the scope of allowed claims before paying any issue fee.

 

 

	8.2	 	LICENSEE agrees to cooperate with the LICENSORS in the prosecution of the U.S. patent
applications to ensure that the applications reflect, to the best of LICENSEE’s knowledge, all
items of commercial and technical interest and importance.

	8.3	 	LICENSORS shall seek patent protection in Europe (including the United Kingdom), Japan and
such other countries as LICENSEE may designate, and LICENSEE shall reimburse LICENSORS within
thirty (30) days for their reasonable, out-of-pocket costs associated with obtaining such
protection; provided, however, that the prosecution of such applications shall be at the
direction of LICENSEE and LICENSEE may elect to prosecute such applications itself or have
them prosecuted through LICENSEE’s agents.

	 	(a)	 	Regardless of whether LICENSORS or LICENSEE prosecute(s) such application, the
resultant patents shall be owned by LICENSORS.
	 
	 	(b)	 	LICENSORS may elect to seek patent protection in countries not designated by
LICENSEE, in which case LICENSORS shall be responsible for all expenses attendant
thereto.
	 
	 	(c)	 	In the event that LICENSEE elects to prosecute foreign patent applications
itself, LICENSORS will be kept informed, will have an opportunity to comment, and shall
have the right to approve such applications, which approval will not be unreasonably
withheld.
	 
	 	(d)	 	If LICENSEE decides to abandon or not pursue any application, LICENSEE shall
notify LICENSORS in a timely manner so that LICENSORS can decide whether or not to
assume the prosecution.

	8.4	 	Any inventions made, during the TERM of this AGREEMENT, with respect to the manufacture, use
or sale of LICENSED PRODUCTS shall be:

	 	(a)	 	the sole property of LICENSEE if made solely by LICENSEE;
	 
	 	(b)	 	the joint property of LICENSEE and LICENSORS if made jointly by LICENSEE and
LICENSORS; and
	 
	 	(c)	 	the sole property of LICENSORS if made solely by LICENSORS;

provided, however, that any such invention made solely by LICENSORS shall be included within
PATENT RIGHTS.

	8.5	 	Upon learning of the infringement by a third party of PATENT RIGHTS, the PARTY learning of
such infringement shall promptly inform the other PARTIES, in writing, of that fact and shall
provide any evidence available pertaining to such infringement.

	 	(a)	 	LICENSEE may elect, within sixty (60) days after notice and at its own expense,
to take whatever steps are necessary to stop the infringement and recover damages.

     (i) If LICENSEE elects to take such action, it will:

	 	(A)	 	keep LICENSORS informed of the steps taken and
the progress of any legal actions taken;
	 
	 	(B)	 	during the pendency of such actions, offset
against royalties owed to LICENSORS on NET SALES in the country or
countries affected by the infringement, the costs of any actions taken
to stop such infringement up to a maximum of fifty percent (50%) of the
royalties owed or owing to LICENSORS;
	 
	 	(C)	 	be entitled to enter into a settlement on such
terms as it may elect;

 

 

	 	(D)	 	retain for its own account, after first
deducting the costs of any actions taken to stop such infringement,
seventy-five percent (75%) of any amounts received in settlement or
awarded as damages with the remaining twenty-five percent (25%) being
paid in equal shares to LICENSORS; and
	 
	 	(E)	 	if unsuccessful in halting such infringement,
be entitled to reduce its royalties owed to LICENSORS, with respect to
the country or countries affected by such infringement, by fifty
percent (50%) during the remaining TERM of the Agreement in each of
those countries; provided that the infringer has achieved ten percent
(10%) or more of the market defined by LICENSED PRODUCTS and the
infringing product in those countries in which the infringement exists.

	 	(ii)	 	If LICENSEE does not elect to take such action within such
period, it will promptly inform LICENSORS, in which event LICENSORS may elect
within thirty (30) days:

	 	(A)	 	to take such action as is required to stop such
infringement, and will then be entitled to settle such actions on such
terms as they may elect (provided, however, that if they grant a
license to the infringer, LICENSEE shall be entitled to reduce its
royalties owed to LICENSORS for the country or countries affected by
fifty percent (50%) and shall be entitled to the benefit of any terms
which are more favorable than those granted to LICENSEE under this
AGREEMENT), will keep LICENSEE informed of the steps taken and the
progress of any legal actions taken, and will be entitled to retain any
amounts received in settlement or awarded in damages; provided,
however, that during the period and for the country or countries in
which LICENSEE does not enjoy exclusivity, or with respect to which
LICENSORS are not able to stop such infringement, LICENSEE shall be
entitled to reduce the applicable royalty rate by fifty percent (50%);
provided that the infringer has achieved ten percent (10%) or more of
the market defined by LICENSED PRODUCTS and the infringing product; or
	 
	 	(B)	 	not to take any action against such infringers,
in which event LICENSEE shall be entitled to elect either:

	 	(1)	 	to terminate this AGREEMENT
pursuant to Section 8.8; or
	 
	 	(2)	 	to reduce the applicable royalty
rate by fifty percent (50%) for each country affected by such
infringement; provided that the infringer has achieved ten
percent (10%) or more of the market defined by LICENSED PRODUCTS
and the infringing product in the countries where such
infringement exists.

	8.6	 	LICENSORS shall give prompt notice to LICENSEE of any inquiry received with respect to the
availability of a license under PATENT RIGHTS or TECHNOLOGY and also of any third party patent
of which LICENSORS become aware that may present an issue of infringement with respect to
LICENSEE’s activities under this AGREEMENT.

 

 

	8.7	 	LICENSEE shall give LICENSORS prompt notice of each claim or allegation received by it that
the manufacture, use or sale of LICENSED PRODUCTS constitutes an infringement of a third party
patent or other intellectual property rights. If such alleged infringement is due to the
incorporation of DUKE TECHNOLOGY or MVP TECHNOLOGY in the LICENSED PRODUCTS, then:

	 	(a)	 	LICENSEE shall have the primary right and responsibility, but not the
obligation, at its own expense to defend and control the defense of any such claims
against LICENSEE, using counsel of its choosing.
	 
	 	(b)	 	During the pendency of any such action, no royalties shall be payable to
LICENSORS on account of NET SALES of LICENSED PRODUCTS in any countries affected by
such action.
	 
	 	(c)	 	LICENSEE’s attorneys’ fees and any amounts agreed to be paid in settlement of
any such action or awarded against LICENSEE as damages, shall be deducted by LICENSEE
from any future royalties due to LICENSORS.
	 
	 	(d)	 	If LICENSEE is required to pay a royalty to any third party as a result of
settlement of any such claim or allegation of infringement, it shall be entitled to
deduct such royalty from the royalties due to LICENSORS under this AGREEMENT.
	 
	 	(e)	 	The settlement of any such action must be approved by LICENSORS, which approval
shall not be unreasonably withheld.

	8.8	 	Independent of any action which LICENSEE or LICENSORS may elect to take pursuant to Section
8.5 or 8.7 with respect to the prosecution, defense or compromise of any such allegation or
claim, LICENSEE may elect to terminate this AGREEMENT solely with respect to the country or
countries to which such claim or allegation pertains. In such event, all rights to the use and
sale of LICENSED PRODUCTS and regulatory filings in that country or those countries shall
revert to LICENSORS.

	8.9	 	In any action brought under this Article 8, the PARTIES not bringing or defending the action
shall, in their sole discretion, be entitled to participate through counsel of their own
choosing in any such action; provided, however, that such participation shall be limited to an
advisory role and counsel for the PARTY bringing or defending the action shall be lead counsel
and the action shall be directed by such PARTY.

	8.10	 	Each PARTY agrees to cooperate with the other PARTIES in any reasonable manner deemed by the
PARTY defending or prosecuting an action under this Article 8, to be necessary in defending or
prosecuting such action.

ARTICLE
9 — REGULATORY, PUBLICATION, OTHER USE, AND EXPORT

	9.1	 	LICENSEE agrees to use its best efforts to have the LICENSED PRODUCTS cleared by the
responsible government agencies requiring such clearance for marketing in those countries in
which LICENSEE intends to sell LICENSED PRODUCTS or award sublicenses.

	 	(a)	 	To accomplish such clearances at the earliest possible dates, LICENSEE agrees
to file, according to the standard practice in the industry, any and all necessary data
with the appropriate government agencies.
	 
	 	(b)	 	Where permitted by law, LICENSEE shall include the names of both LICENSORS as
co-registrants on all regulatory filings.

 

 

	9.2	 	LICENSEE further agrees that the right of publication of the TECHNOLOGY shall reside in the
inventor(s) and other personnel of LICENSORS and the LICENSORS shall use their best efforts to
provide a copy of such publication forty-five (45) days in advance of publication for review
by LICENSEE. If LICENSEE determines that the publication by LICENSORS will disclose any trade
secrets, LICENSORS shall delay publication for an additional sixty (60) days after the
forty-five (45) day period to allow patent applications to be filed.

	9.3	 	It is agreed that, notwithstanding any provisions herein, LICENSORS are free to use the
TECHNOLOGY and PATENT RIGHTS for their own non-commercial purposes, whether educational,
teaching, research or clinical purposes, without payment of royalties or other fees.

	9.4	 	LICENSEE and LICENSORS agree to comply with all United States laws and regulations
controlling the export of technical data, computer software, laboratory prototypes and other
commodities and technology.

ARTICLE
10 — DURATION AND TERMINATION

	10.1	 	This AGREEMENT shall become effective upon the EFFECTIVE DATE and shall remain in full force
and effect, on a country-by-country basis, for the longer of: ten (10) years from the date of
first sale of LICENSED PRODUCTS in each country, or the date of expiration of the
last-to-expire patent, of those patents included in the PATENT RIGHTS, in each country; such
period of time with respect to each country being known as the TERM of this AGREEMENT;
provided, however, that this AGREEMENT may be terminated in one or more countries prior to the
TERM in accordance with Sections 8.8, 10.2, 10.3 or 10.6.

	10.2	 	LICENSEE may, prior to expiration of the TERM, elect to terminate this AGREEMENT with respect
to any one or more countries in the TERRITORY, at any time, effective after the first
anniversary of the EFFECTIVE DATE, by giving LICENSORS written notice at least six (6) months
prior to each such termination. On the effective date of each such termination, LICENSEE shall
cease the manufacture, use and sale of LICENSED PRODUCTS in the country or countries in which
LICENSEE has elected to terminate prior to expiration of the TERM.

	10.3	 	As used in this Section 10.3, PARTY shall mean either (1) BTG or (2) MVP and DUKE, jointly.
Any PARTY may immediately terminate this AGREEMENT for fraud, willful misconduct, or illegal
conduct of the other PARTY upon written notice of same to such PARTY. Except as provided
above, if a PARTY fails to fulfill any of its material obligations under this AGREEMENT, the
non-breaching PARTY may terminate this AGREEMENT, with respect to the country or countries
affected, upon written notice to the other PARTY, as provided below. Such notice must contain
a full description of the event or occurrence constituting a breach of this AGREEMENT. A PARTY
receiving notice that it has breached the AGREEMENT will have the opportunity to cure that
breach within thirty (30) days of the receipt of notice. A PARTY’s ability to cure a breach
will apply only to the first two (2) material breaches properly noticed to that PARTY under
the terms of this AGREEMENT. Any subsequent material breach by that PARTY will entitle the
other PARTY to terminate this AGREEMENT immediately upon proper notice to such PARTY without a
cure period. In the event that a PARTY commits such a subsequent breach, the non-breaching
PARTY may, at its option and in addition to any other remedies it may have in law or in
equity, terminate this AGREEMENT for

 

 

	 	 	default by sending to the breaching PARTY written notice of termination, effective
immediately upon receipt.
	10.4	 	Upon the termination of this AGREEMENT in one or more countries prior to the end of the TERM,
LICENSEE shall notify LICENSORS of the quantity of LICENSED PRODUCTS that LICENSEE then has in
inventory with respect to the country or countries for which the termination is effective and
LICENSEE shall then have a license in each such country to sell that amount of LICENSED
PRODUCTS, but no more, provided that the LICENSEE shall pay the royalty thereon at the rate
and at the time provided for herein.
	 
	10.5	 	If this AGREEMENT is terminated pursuant to Section 8.8 or pursuant to this Article 10 by
either LICENSEE or LICENSORS prior to the end of the TERM in one or more countries, then all
intellectual property rights conveyed by LICENSORS to LICENSEE under this AGREEMENT
(including, without limitation: rights in the mark, PURICASETM, approved and
pending regulatory applications, Orphan Drug Designations, Drug Master Files, sublicenses,
preclinical data and clinical data) shall revert to LICENSORS with respect to those countries.
	 
	10.6	 	If, during the TERM of this AGREEMENT, a PARTY shall become bankrupt or insolvent, or if the
business of a PARTY shall be placed in the hands of a receiver or trustee, whether by the
voluntary act of such PARTY or otherwise, or if a PARTY shall cease to exist as an active
concern, then if the PARTY experiencing such event is:

	 	(a)	 	LICENSEE, then this AGREEMENT shall terminate immediately, and all rights to
LICENSED PRODUCTS and the TECHNOLOGY shall revert to the LICENSORS or their respective
successors or assignees;
	 
	 	(b)	 	MVP or DUKE, then the rights granted to LICENSEE under this AGREEMENT by such
LICENSOR shall become paid-up, exclusive, and irrevocable, this AGREEMENT shall
terminate with respect to such LICENSOR, and LICENSEE shall make such payments to the
remaining LICENSOR that it would have received absent termination of the AGREEMENT with
respect to the other LICENSOR.

	10.7	 	Expiration or termination of this AGREEMENT shall be without prejudice to or limitation on
any other remedies or any accrued obligations of any of the PARTIES.

ARTICLE
11 — CONFIDENTIAL INFORMATION

	11.1	 	Confidential information (“INFORMATION”) shall mean all information provided by LICENSORS to
LICENSEE or by LICENSEE to LICENSORS and identified as confidential at the time of disclosure.
Specifically excepted from this definition is all information that is:

	 	(a)	 	already known by the receiving PARTY at the time of disclosure, as demonstrated
by clear and convincing evidence contemporaneous with or preceding the disclosure;
	 
	 	(b)	 	publicly disclosed through no improper act or omission of the receiving PARTY;
	 
	 	(c)	 	rightfully received by the receiving PARTY from a third party without any
obligation of confidentiality; or
	 
	 	(d)	 	disclosed pursuant to any judicial or government requirement or order, provided
that the receiving PARTY takes reasonable steps to provide the disclosing

 

 

	 	 	 	PARTY with sufficient prior notice in order to allow the disclosing PARTY to contest
such requirement or order; or
	 	(e)	 	independently developed by DUKE alone, without reference or access to the
disclosing PARTY’s INFORMATION.

	11.2	 	In the event the receiving PARTY is required by law, regulation or court order to disclose
any of the disclosing PARTY’s INFORMATION, the receiving PARTY will promptly notify the
disclosing PARTY in writing prior to making any such disclosure in order to facilitate the
disclosing PARTY seeking a protective order or other appropriate remedy from the proper
authority. The receiving PARTY agrees to cooperate with the disclosing PARTY in seeking such
order or other remedy. The receiving PARTY further agrees that if the disclosing PARTY is not
successful in precluding the requesting legal body from requiring the disclosure of the
INFORMATION, it will furnish only that portion of the INFORMATION that is legally required and
will exercise all reasonable efforts to obtain reliable assurances that confidential treatment
will be accorded the INFORMATION.

	11.3	 	The receiving PARTY agrees to hold INFORMATION in trust and confidence for the disclosing
PARTY, using the same care and discretion that the receiving PARTY uses with respect to its
own proprietary information that it considers confidential and, in any event, at least the
care that is standard in the industry for confidential, proprietary information of another.
The receiving PARTY will not use such information for any purpose except those expressly set
forth in this AGREEMENT and will not disclose such information to any third party without the
prior written authorization from the disclosing PARTY.

	 	(a)	 	Any INFORMATION that MVP discloses to BTG related to PEGylation of proteins or
to purification or analysis of PEG-protein conjugates may not be disclosed to DUKE.
Except as provided in the foregoing sentence, any other INFORMATION that MVP discloses
to BTG may be disclosed by BTG to DUKE.
	 
	 	(b)	 	Obligations of this Section 11.3 shall remain in effect during the TERM of this
AGREEMENT and for a period of five (5) years after the expiration or termination of the
AGREEMENT in the last-to-expire or last-to-terminate country, whichever occurs later.
	 
	 	(c)	 	No provision contained in this AGREEMENT shall be read to preclude BTG from
providing PEGylated uricase to DUKE for research or clinical purposes, or from
informing DUKE of the number of strands and molecular weight of the PEG and other
descriptive characteristics of the PEGylated uricase provided to DUKE.
	 
	 	(d)	 	Notwithstanding the foregoing, DUKE shall not be obligated to hold in
confidence another PARTY’s INFORMATION for longer than five (5) years after such
INFORMATION is disclosed to it.

ARTICLE
12 — LAW TO GOVERN

	12.1	 	The laws of the State of California will govern the construction, interpretation and
performance of this AGREEMENT, without giving effect to conflicts of law rules thereof.

 

 

ARTICLE
13 — ASSIGNMENT

	13.1	 	No PARTY may assign any of its rights or delegate any of its duties under this AGREEMENT
without the prior written consent of the other PARTIES except:

	 	(a)	 	In connection with the sale of a PARTY’s entire business operation; or
	 
	 	(b)	 	In connection with the assignment of the rights or delegation of the duties of
any PARTY to any of its AFFILIATES.

	13.2	 	Any unauthorized attempted assignment or delegation shall be null and void and of no force or
effect.

ARTICLE
14 — NOTICES

	14.1	 	Any notice or other communication required or permitted under this AGREEMENT will be in
writing and will be deemed given as of the date it is: (a) delivered by hand, or (b) mailed,
postage prepaid, first class, certified mail, return receipt requested, to the PARTY/PARTIES
at the address listed below or subsequently specified in writing, or (c) sent, postage
prepaid, return receipt requested, by courier service, to the PARTY/PARTIES at the address
listed below or subsequently specified in writing:

If to the LICENSORS:

Mountain View Pharmaceuticals, Inc.

3475-S Edison Way

Menlo Park, California 94025

Attn.: Merry R. Sherman, Ph.D.

AND:

Office of Science and Technology

North Building, Room 230

Research Drive

Duke University, Box 90083

Durham, North Carolina 27708

Attn.: License Administrator

With a copy to:

     Office of the University Counsel

     Allen Building, Room 011

     Duke University

     Durham, North Carolina 27708

If to the LICENSEE:

Bio-Technology General Corporation

70 Wood Avenue South

Iselin, New Jersey 08830

Attn.: Sim Fass, Ph.D.

ARTICLE
15 — INDEMNITY, INSURANCE AND REPRESENTATIONS

	15.1	 	LICENSEE agrees to indemnify, hold harmless and defend LICENSORS, their officers, employees,
and agents, against any and all claims, suits, losses, damages, costs, fees, and expenses,
including reasonable attorneys’ fees, asserted by third parties, both government

 

 

	 	 	and non-government, resulting from or arising out of LICENSEE’s exercise of the rights
granted under this AGREEMENT. LICENSEE shall not be responsible for the intentional
wrongdoing of LICENSORS.
	 
	15.2	 	LICENSORS agree to indemnify, hold harmless and defend LICENSEE, its officers, employees, and
agents, against any and all claims, suits, losses, damages, costs, fees, and expenses,
including reasonable attorneys’ fees, asserted by third parties, both government and
non-government, resulting from or arising out of LICENSORS’s exercise of their rights and
obligations under this AGREEMENT. LICENSORS shall not be responsible for the intentional
wrongdoing of LICENSEE.
	 
	15.3	 	The PARTIES shall maintain in force at their sole cost and expense general liability
insurance coverage in an amount reasonably sufficient to protect against liability under this
Article 15. LICENSEE also shall maintain in force at its sole cost and expense product
liability insurance coverage in an amount reasonably sufficient to protect against liability
under this Article 15. Each PARTY shall have the right to request and to receive copies of the
appropriate certificates of insurance from the other PARTIES for the purpose of ascertaining
the sufficiency and currency of such coverage.
	 
	15.4	 	Except as provided in Section 15.8, nothing in this AGREEMENT shall be deemed to be a
representation or warranty by LICENSORS of the validity of any of the patents or the accuracy,
safety, efficacy, or usefulness, for any purpose, of any TECHNOLOGY.
	 
	15.5	 	LICENSORS shall have no obligation, expressed or implied, to supervise, monitor, review or
otherwise assume responsibility for the production, manufacture, testing, clinical trials,
marketing or sale of any LICENSED PRODUCTS, and LICENSORS shall have no liability whatsoever
to LICENSEE, its officers, employees or agents for or on account of any injury, loss, or
damage, of any kind or nature, sustained by, or any damage assessed or asserted against, or
any other liability incurred by or imposed upon LICENSEE, its officers, employees or agents or
any other person or entity, arising out of or in connection with or resulting from LICENSEE’s:

	 	(a)	 	production, use, or sale of any LICENSED PRODUCTS;
	 
	 	(b)	 	use of any TECHNOLOGY; or
	 
	 	(c)	 	advertising or other promotional activities with respect to any of the
foregoing.

	15.6	 	MVP hereby represents and warrants to BTG and DUKE that MVP has the right to grant the
licenses set forth herein under PATENT RIGHTS and MVP TECHNOLOGY, including the license to the
technical know-how summarized in Exhibit B, and to the use of the trademark,
PURICASETM.
	 
	15.7	 	DUKE hereby represents and warrants to BTG and MVP that DUKE has the right to grant the
licenses set forth herein under PATENT RIGHTS and DUKE TECHNOLOGY, including the license to
the technical know-how and materials summarized in Exhibit A.
	 
	15.8	 	Each of the LICENSORS hereby separately represents and warrants to BTG that:

	 	(a)	 	it has no actual knowledge, as of the EFFECTIVE DATE, that the use of
TECHNOLOGY for the manufacture, use or sale of LICENSED PRODUCTS will infringe any
patent or other intellectual property right of any third party in any country in the
world, and that, if at any time during the TERM of this AGREEMENT, it becomes aware of
any such information, it will promptly disclose such to BTG;

 

 

	 	(b)	 	it has no actual knowledge, as of the EFFECTIVE DATE, of any prior art that
would raise any issue concerning the validity of any patents issued or to issue on any
applications which are included in PATENT RIGHTS, and that if at any time during the
TERM of this AGREEMENT, it becomes aware of any such information, it will promptly
disclose such to BTG;
	 
	 	(c)	 	it is not aware of any other agreements, amendments or licenses that affect its
authority or ability to enter into this AGREEMENT;
	 
	 	(d)	 	prior to the execution of this AGREEMENT, it has not assigned, encumbered,
pledged, mortgaged, used as collateral, granted a security interest or lien in or
otherwise engaged in any action that affects its ability to grant LICENSEE the rights
granted pursuant to the terms of this AGREEMENT; and
	 
	 	(e)	 	during the TERM of this AGREEMENT, it will not engage in any action that could
reasonably be anticipated to adversely affect its ability to grant LICENSEE the rights
to manufacture, use and sell LICENSED PRODUCTS anywhere in the world pursuant to the
terms of this AGREEMENT.

ARTICLE
16 — USE OF A PARTY’S NAME

	16.1	 	Except for the rights granted to LICENSEE herein with respect to the mark
PURICASETM, no PARTY to this AGREEMENT will, without the prior written
consent of another party:

	 	(a)	 	use in advertising, publicity or otherwise, the name of any employee or agent,
any trade-name, trademark, trade dress, service mark, symbol, or any abbreviation,
contraction or simulation thereof owned by another PARTY; or
	 
	 	(b)	 	represent, either directly or indirectly, that any product or service of
another PARTY is a product or service of the representing PARTY or that it is made in
accordance with or utilizes the information or documents of another PARTY.

	16.2	 	No PARTY will originate any publicity, news release or other public announcement or comment,
written or oral, related to this AGREEMENT without the prior written consent of the other
PARTIES, except as may be required by law. The PARTY making any announcement, which it
reasonably believes to be required by law, will first give the other PARTIES an opportunity to
review the form and content of any such announcement and comment upon it before it is made.

Notwithstanding the foregoing, LICENSORS acknowledge that BTG is a publicly traded company,
and hereby consent to BTG’s disclosure of this AGREEMENT and its relationship with LICENSORS
in its filings with the Securities and Exchange Commission and its disclosures to its
stockholders.

ARTICLE
17 — SEVERABILITY

	17.1	 	Each clause of this AGREEMENT is distinct and severable. If any clause is deemed illegal,
void or unenforceable, it is the PARTIES’ intent that all other clauses or portions of this
AGREEMENT shall remain in effect to the maximum extent possible.

 

 

ARTICLE
18 — WAIVER

	18.1	 	The failure of any PARTY in any instance to insist upon the strict performance of the terms
of this AGREEMENT will not be construed to be a waiver or relinquishment of any of the terms
of this AGREEMENT, either at the time of the PARTY’s failure to insist upon strict performance
or at any subsequent time, and such terms will continue in full force and effect.

ARTICLE
19 — TITLES

	19.1	 	All titles and article headings contained in this AGREEMENT are inserted only as a matter of
convenience and reference. They do not define, limit, extend or describe the scope of this
AGREEMENT or the intent of any of its provisions.

ARTICLE
20 — ENTIRE UNDERSTANDING

	20.1	 	This AGREEMENT represents the entire understanding between the LICENSEE and the LICENSORS,
and supersedes all other agreements, expressed or implied, between the LICENSEE and the
LICENSORS, with the sole exception of the agreement dated July 30, 1998 among BIRD, BTG and
MVP.

     IN WITNESS WHEREOF, the PARTIES have caused this AGREEMENT to be executed by their duly
authorized representatives as of the EFFECTIVE DATE.

	 	 	 	 	 
	 	MOUNTAIN VIEW PHARMACEUTICALS, INC.

 	 
	 	By:  	/s/ Merry R. Sherman, Ph.D.
 	 
	 	 	Merry R. Sherman, Ph.D 	 
	 	 	President 	 
	 

	 	 	 	 	 
	 	DUKE UNIVERSITY

 	 
	 	By:  	/s/ Robert L. Taber Ph.D.
 	 
	 	 	Robert L. Taber, Ph.D. 	 
	 	 	Associate Vice-Chancellor and Director,
Office of Science and Technology 	 
	 

	 	 	 	 	 
	 	BIO-TECHNOLOGY GENERAL CORP.

 	 
	 	By:  	/s/ Robert M. Shaw
 	 
	 	 	Robert M. Shaw 	 
	 	 	Vice President, General Counsel 	 

	 	 	 	 	 

 

 

Exhibit A

Summary of Know-how, Information and Materials to be Provided by DUKE to BTG as

Part of DUKE TECHNOLOGY

[**]

 

Exhibit B

Summary of Know-how, Information and Materials to be Provided by MVP

to BTG as Part of MVP TECHNOLOGY

[**]

 

Exhibit C

Patents and Patent Applications included within PATENT RIGHTS

(To Be Amended from Time to Time during the TERM)

[**]EX-10.25

 

Exhibit 10.25

CONFIDENTIAL
MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

SUPPLY AGREEMENT

BETWEEN

WATSON PHARMA, INC.

AND

SAVIENT PHARMACEUTICALS, INC.

 

 

Table of Contents

	 	 	 	 	 
	SECTION 1 DEFINITIONS
	 	 	i	 
	SECTION 2 SUPPLY AND PURCHASE OF PRODUCTS
	 	iii
	SECTION 3 PRICING
	 	vi
	SECTION 4 FORECASTS, ORDERS
	 	viii
	SECTION 5 SPECIFICATIONS
	 	ix
	SECTION 6 TERM
	 	xii
	SECTION 7 TERMINATION
	 	xii
	SECTION 8 DELIVERY; INVENTORY
	 	xv
	SECTION 9 DEFECTIVE PRODUCTS
	 	xv
	SECTION 10 REGULATORY MATTERS
	 	xvi
	SECTION 11 FORCE MAJEURE
	 	xix
	SECTION 12 INSURANCE
	 	xix
	SECTION 13 CONFIDENTIALITY
	 	xx
	SECTION 14 PUBLIC ANNOUNCEMENTS
	 	xx
	SECTION 15 REPRESENTATIONS AND WARRANTIES
	 	xxi
	SECTION 16 INDEMNIFICATION
	 	xxii
	SECTION 17 DISPUTE RESOLUTION
	 	xxiii
	SECTION 18 MISCELLANEOUS
	 	xxiii

LIST
OF EXHIBITS

A. Product,
Specifications and Packaging

B. Initial
Finished Product Prices

C. Adverse
Event Reporting Procedures

D. Initial
Purchase Order Forecast

E. Quality
Requirements

F. Form
of Press Release

 

 

SUPPLY AGREEMENT

     SUPPLY AGREEMENT, dated as of June 12, 2006, by and between Savient Pharmaceuticals, Inc., a
Delaware corporation (“Seller”), and Watson Pharma, Inc., a Delaware corporation
(“Purchaser”).

     WHEREAS, Seller would like to make and sell the Products (as defined below) to Purchaser, and
Purchaser would like to purchase the Products from Seller pursuant to the terms of this Agreement;

     NOW, THEREFORE, in consideration of the mutual promises, covenants and agreements hereinafter
set forth, the parties hereto agree as follows:

SECTION 1

DEFINITIONS

     As used throughout this Agreement and any exhibits, schedules or attachments hereto, each of
the following terms shall have the respective meaning set forth below:

     1.1 “Additional Amount” shall have the meaning given in Section 2.2.3.

     1.2 “Affiliate” of a Party shall mean any entity that, directly or indirectly, controls, is
controlled by, or is under common control with such entity. For the purposes of this definition,
the term “controls” (including, with correlative meanings, the terms “controlled by” and “under
common control with”) as used with respect to any Party, shall mean the possession (directly or
indirectly) of more than 50% of the outstanding voting securities or other equity or voting
interest of an entity.

     1.3 “ANDA” shall mean an Abbreviated New Drug Application filed with the FDA.

     1.4 “Bankruptcy Code” shall have the meaning given in Section 7.3.

     1.5 “Bankruptcy Law” shall have the meaning given in Section 7.3.

     1.6 “Commercially Reasonable Efforts” shall mean, with respect to a Party, those commercially
reasonable efforts that such Party is making in similar circumstances relative to other products in
its portfolio with respect to production and/or marketing, distribution and sales of its own
products that are in production or that are being marketed, distributed and sold at that time, as
applicable. Commercially Reasonable Efforts shall be in accordance with the efforts and resources
that the Party would use for a product owned by it or to which it has rights, which is of similar
market potential at a similar stage in its product life, taking into account the competitiveness of
the marketplace, the proprietary position of the applicable active ingredient, the regulatory
structure involved, and the profitability of the product.

     1.7 “Damages” shall have the meaning given in Section 16.1.

     1.8 “Delivery Price” shall have the meaning given in Section 3.1.

     1.9 “Effective Date” shall mean the date of this Agreement.

i

 

     1.10 “Equivalent Product” shall mean any product, other than a Product that Seller is
obligated to supply to Purchaser hereunder, which (i) is manufactured by a Party pursuant to an
ANDA which was approved by the FDA, which ANDA was filed on the basis of the original NDA for the
brand equivalent of such Product or (ii) is otherwise a generic version of the brand equivalent of
such Product.

     1.11 “Existing Inventory” shall mean all Product manufactured by Seller into final tableted
form prior to [**] with the following lot numbers: A18061; C400715; C400721; C500173;
C500174; C500175, and; 4A3069.

     1.12 “FDA” shall mean the U.S. Food and Drug Administration, and any successor or replacement
agency.

     1.13  “Finished Product Price” shall mean the aggregate cost to manufacture and/or Label
Product, on a batch by batch basis,

		
	 	     (i) if Product is manufactured and/or Labeled by Seller or an Affiliate of
Seller the sum of Seller’s (a) [**], (b) [**] and (c) [**]; or
	 
	 	     (ii) if such Product is manufactured and/or Labeled by a Third Party
manufacturer, the sum of (a) [**] and (b) [**].

All costs included in Manufacturing Costs shall be calculated in accordance with U.S. generally
accepted accounting principles, consistently applied to the manufacture of all products produced in
the facility or facilities in which such Product is manufactured and/or Labeled. [**]

     1.14 “Force Majeure Event” shall have the meaning given in Section 11.

     1.15 “Gross Margin” shall have the meaning given in Section 3.1.

     1.16 “Indemnity Claim” shall have the meaning given in Section 16.3.

     1.17 “Initial Purchase Order” shall have the meaning given in Section 2.2.1.

     1.18 “Label”, “Labeled” or “Labeling” shall mean all labels and other written, printed or
graphic matter upon (i) any packaging, container or wrapper utilized with the Products, or (ii) any
written material accompanying the Products, including package inserts; or as the context requires,
the act of applying and/or using the same.

     1.19 “Latent Defect” shall mean any instance where a lot of a Product fails to conform to the
applicable Specifications or is otherwise defective or fails to conform to the warranties given by
Seller herein, and such failure would not be discoverable upon reasonable physical inspection or
standard testing of such Product upon receipt by Purchaser in accordance with Purchaser’s standard
operating procedures.

     1.20 “Launch Quantity” shall have the meaning given in Section 2.2.1.

     1.21 “Material Change” shall have the meaning given in Section 5.2.1

     1.22 “NDA” shall mean a New Drug Application filed with the FDA.

     1.23 “Net Sales” shall mean, with respect to any Product, the revenues derived from the sale
by Purchaser, its Affiliates, licensees and assignees from the sale of a Product to independent
third parties, less: (i) all normal and customary discounts (such as cash discounts, volume
discounts, chargebacks, allowances (including shelf stock adjustments and promotional allowances
that are not selling or marketing-related operational expenses), government mandated rebates and
other rebates, credits, and Product returns), (ii) freight, shipping, insurance costs relating to
the shipment of the Product, duties and taxes; and (iii) bad debt related to the Product (as such
bad debts are actually

 

 

incurred). Net Sales shall be determined on an accrual basis (except for clause (iii) above)
in accordance with generally accepted accounting principles in the Territory, applied on a basis
consistent with Purchaser’s annual audited financial statements. Subject to the foregoing,
Purchaser will not deduct any marketing, selling, advertising or distribution expenses of any kind
to determine Net Sales.

     1.24 “Packaging” shall mean all primary containers, Labels, cartons, shipping cases or any
other like matter used in packaging or accompanying the Products; or as the context requires, the
act of applying and/or using the same.

     1.25 “Party” shall mean Seller or Purchaser and, when used in the plural, shall mean Seller
and Purchaser.

     1.26 “Patent Defect” shall mean any instance where a lot of a Product fails to conform to the
applicable Specifications or is otherwise defective or fails to conform to the warranties given by
Seller herein, and such failure is discoverable upon reasonable physical inspection or standard
testing of such Product upon receipt by Purchaser in accordance with Purchaser’s standard operating
procedures.

     1.27 “Product” or “Products”, as applicable, shall mean each of oxandrolone 2.5mg tablets (the
“2.5mg Product”) and oxandrolone 10mg tablets (the “10mg Product”), collectively the Products and,
any other products the parties agree to include herein; Product shall not include any branded
version of oxandrolone either currently offered for sale or offered for sale in the future by
Seller, whether or not of the same dosage strength or form.

     1.28 “Purchase Price” shall have the meaning give in Section 3.1.

     1.29 “Purchaser Trademarks” shall have the meaning given in Section 5.4.

     1.30 “Quality Requirements” shall have the meaning give in Section 5.3.

     1.31 “Remainder Payment” shall have the meaning given in Section 3.1.

     1.32 “Specifications” shall mean the specifications for the design, composition, manufacture,
packaging, and/or quality control of each of the Products, as set forth on Exhibit A
attached hereto and made a part hereof, as the same may hereafter be modified by mutual agreement
of the parties in writing.

     1.33 “Start Date” shall have the meaning given in Section 2.2.3.

     1.34 “Territory” shall mean the United States of America, including its territories and
possessions and military bases and possessions (including, but not limited to, the Commonwealth of
Puerto Rico).

SECTION 2

SUPPLY AND PURCHASE OF PRODUCTS

     2.1 Supply and Purchase Obligations.

          2.1.1 During the Distribution Term, Seller shall manufacture, or have manufactured by a third
party, and exclusively supply Purchaser with Products for sale and distribution in the

 

 

Territory. Seller shall supply Purchaser with those quantities of Products as are ordered by
Purchaser pursuant to this Agreement. In the event Seller has any Product manufactured by an
unaffiliated third party, Seller shall (i) notify the Purchaser as to the identity of the third
party manufacturer prior to the commencement of supply, and (ii) use its best efforts to obtain
from such third party manufacturer rights for the benefit of Purchaser as set forth in Section 5.3,
5.5, 10.3, 10.4, 10.9 and 10.10 hereto. During the Distribution Term (subject to the provisions of
Section 4.5) Purchaser shall purchase from Seller 100% of Purchaser’s requirements for the Products
in the Territory.

          2.1.2 During the Distribution Term (and subject to the provisions of Section 4.5), Purchaser
shall purchase from Seller the Products solely for distribution and sale in the Territory. During
the Term, Seller and its Affiliates shall not, and shall not directly or indirectly grant to any
other person or entity the right to, sell or distribute the Products and/or Equivalent Product in
the Territory, and Seller shall not directly or indirectly cooperate with any other person or
entity with respect to, or supply products or services for, the sale or distribution of the
Products and/or Equivalent Product in the Territory. Nothing in this Agreement shall prevent the
Seller from marketing or selling, or granting third parties the right to market or sell (i) any
formulation, dosage or strength of oxandrolone, utilizing any method of delivery, under the brand
name Oxandrin® or (ii) any other branded formulations, dosages or strengths of oxandrolone, in each
case, other than those Products identified in Exhibit A.

          2.1.3 During the Term, Purchaser shall not, directly or knowingly and indirectly, (i) solicit
customers for the Product, or make sales of the Product, or establish or maintain any branch or
distribution depot for the Product, outside of the Territory, or assist any party in doing so or
(ii) solicit customers for an Equivalent Product, or make sales of an Equivalent Product, or
establish or maintain any branch or distribution depot for an Equivalent Product, within the
Territory, or assist any party in doing so. If at any time Purchaser, directly or knowingly and
indirectly, markets, sells, or distributes the Product outside the Territory, Seller may suspend
all sales of the Product to Purchaser until Purchaser takes appropriate actions to cease such
sales. At such time as Purchaser learns that a customer is directly or indirectly using, marketing,
selling or distributing Products outside of the Territory, or that such customer is assisting any
other party to do so, then Purchaser shall cease making sales of Products to such customer until
such a time as customer ceases making sales outside of the Territory and Purchaser shall
immediately notify Seller in writing of such occurrence and take reasonable actions within its
legal rights and powers to cause such third parties to cease making such sales of the Product
outside the Territory.

          2.1.4
[ ** ], nothing in this
Agreement shall prohibit Purchaser from undertaking its own development of any Equivalent Product,
seeking regulatory approval of any such Equivalent Product, or undertaking manufacturing
development and qualification, and limited manufacture (including third party manufacturing) of
stability batches and validation batches of Equivalent Product, in each case solely for purposes of
seeking regulatory approval for such Equivalent Product; provided, however, that
Purchaser shall not be permitted to sell any Equivalent Product which it so manufactures during the
Term of this Agreement. [ ** ]

     2.2 Commencement of Supply.

          2.2.1 Seller shall be obligated to commence supply of the Products to Purchaser within ninety
(90) days of receipt of a binding purchase order of Products from Purchaser in accordance with the
terms and conditions of this Agreement (“Initial Purchase Order”). The quantities in such Initial
Purchase Order shall be discussed in good faith and mutually agreed

 

 

between
the parties (“Launch Quantity”). Subject to the immediately preceding sentence, the nonbinding forecast for the
Initial Purchase Order is attached as Exhibit D to this Agreement. It is
further agreed that Seller shall use best commercial efforts to supply a total
amount of [**] bottles of the 2.5mg Product, [**], as soon as commercially
practicable but in no event later than ninety (90) days from the date of
receipt by Purchaser of the Launch Quantities. All orders of Product by
Purchaser shall be made in units which comprise whole batch amounts; the
delivery of such Product shall be in amounts that reflect the actual batch
yield where such yield does not deviate from the defined range ([**] bottles
per batch for 2.5mg Product and [**] bottles per batch for 10mg Product).

          2.2.2 Upon receipt of the Initial Purchase Order, Seller shall, as promptly as commercially
feasible and using diligent efforts (but in any event no later than ninety (90) days after receipt
of such Initial Purchase Order or later date as requested in writing by Purchaser) supply to
Purchaser the quantities of the applicable Product which are indicated on the Initial Purchase
Order for such Product. In addition to any other right or remedy available to Purchaser, upon any
failure by Seller to provide all of the Products in the Initial Purchase Order within the specified
and mutually agreed upon time schedule, then Purchaser shall have the right, but not the
obligation, to terminate this Agreement, without penalty to either Party, with respect to any or
all of such Products (at Purchaser’s discretion) on thirty (30) days prior written notice to
Seller.

          2.2.3 The parties agree that they shall cooperate to determine when an Equivalent Product may
become available to the marketplace. However, Seller shall, at its sole discretion, designate on
which date the Products will be distributed in the Territory by Purchaser (“Start Date”)
and provide Purchaser with reasonable written notice thereof. It is specifically contemplated and
agreed that the 2.5mg Product and the 10mg Product may each have a separate and distinct Start Date
based upon the availability of an Equivalent Product in the respective dosage forms, and that
Purchaser shall only sell that Product for which Seller has provided explicit approval and for
which a designated Start Date has been specified in writing by Seller.

          2.2.4 Prior to the Start Date, Purchaser shall have in place with all significant wholesalers,
chain and other drug supply and pharmacy outlets, a communication advising such entities of the
Product’s pending availability. Consequently, if any Product supplied to Purchaser under this
Agreement is delivered by Purchaser to any third party earlier than two (2) business days prior to
the applicable Start Date, then Purchaser shall pay to Seller, as liquidated damages (the
“Additional Amount”) an amount equal to (X) the number of units of such Product shipped or
distributed by Purchaser to any third party prior to the applicable Start Date times (Y) Seller’s
average net selling price for Seller’s branded version of such Product, less (Z) the amounts paid
or payable by Purchaser to Seller for such Product under Section 3 below.

          Notwithstanding the foregoing, with Seller’s prior written approval, Purchaser may ship
Product to third party purchasers earlier than two (2) business days prior to the Start Date
without penalty if such Product is held by third party purchasers thereof in isolation and not
available for sale, resale or dispensing until the applicable Start Date; provided, however, that
Purchaser shall obtain from any third party purchasers of Product contemplated hereunder binding
assurances of non-release prior to the Start Date. To the extent any third party purchaser
releases Product for sale, resale or dispensing prior to the Start Date, then Purchaser shall be
liable to Seller for the Additional Amount with respect to such Product as calculated above. The
Additional Amount shall be Seller’s sole and exclusive remedy (whether arising in contract, tort or
otherwise) for the sale prior to the applicable Start Date of any Product by Purchaser and in no
event shall such sale be considered or deemed as a breach hereunder. Purchaser shall deliver to
Seller written notice of its initial shipment of Product to the retail trade within twenty-four
(24) hours of such shipment.

          2.2.5 Seller shall supply to Purchaser, and Purchaser shall accept from Seller subject to all
applicable terms and conditions herein, Launch Quantities of Product from Seller’s Existing
Inventory provided that such Existing Inventory complies with the terms and conditions of this
Agreement. Anything to the contrary notwithstanding, to the extent that any Existing Inventory is
sold to Purchaser by Seller and subsequent thereto Purchaser is unable to sell such Existing

 

 

Inventory because its remaining expiry dating is equal to or less than twelve (12) months,
Purchaser may return such quantities of Existing Inventory to Seller and Seller shall thereafter,
in accordance with the applicable terms and conditions herein, refund to Purchaser one hundred
percent (100%) of the Delivery Price actually paid for such quantities as are actually returned to
Seller.

SECTION 3

PRICING

     3.1 Purchase Prices. The purchase price (“Purchase Price”) paid by Purchaser
for each Product delivered by Seller shall be paid in two installments. The first installment (the
“Delivery Price”) shall be a payment equal to the number of units of such Product delivered
by Seller to Purchaser pursuant to [**] of such Product. The second installment (the “Remainder Payment”) shall be a
quarterly payment equivalent to [**] percent ([**]%) of Purchaser's Gross Margin (as defined below) on the sale of such Product for each calendar quarter during the Term hereof. For purposes
of this Agreement “Gross Margin” for a particular
calendar quarter shall be equivalent to [**] of Product sold during the quarter in question. Purchaser shall provide to Seller within
thirty (30) days of the end of each quarter a reasonably detailed report which sets forth the Gross
Margin for the quarter just completed.

     3.2 Delivery Price Adjustment. The Delivery Price for Product in effect during any
calendar year may be adjusted by Seller upon notice to Purchaser during such calendar year to
reflect any actual increase in Seller’s Manufacturing Cost for Product.

     3.3 Shipping Terms. The prices charged by Seller to Purchaser shall be FCA (Incoterms
2000), Seller’s facility in the Territory at which finished goods are packaged for shipment to
Purchaser. All deliveries must be accompanied by a packing slip that describes the Products and
identifies the purchase order number and the shipment’s destination.

     3.4 Payment Terms. The Delivery Price for each Product shall be paid by Purchaser
within sixty (60) days from the date of delivery of such Product. The Remainder Payment shall be
paid to Seller within sixty (60) days after the end of each calendar quarter. All payments shall
be made in United States dollars.

     3.5 Negative Gross Margin.

          3.5.1 To the extent the Gross Margin is negative in any particular quarter or quarters
hereunder Seller shall reimburse Purchaser for [**] percent ([**]%) of the amount of any such negative Gross Margin
within sixty (60) days after the end of (i) such calendar quarter or (ii) the expiration or
termination of this Agreement, as the case may be.

          3.5.2 For any quarter in which Purchaser claims a negative Gross Margin, Seller shall have the
right to have Seller’s independent public accountants (reasonably acceptable to Purchaser) conduct
an audit of Purchaser’s financial records, as such information relates to Net Sales and the
calculation of Gross Margin with respect to each Product during the quarter in question, for a
period of twelve (12) months following receipt of Purchaser’s notice to Seller of such negative
Gross Margin; provided, however, that this right may not be exercised more than once in any
calendar year. Any audit conducted pursuant to this Section 3.5.2 shall not count against the
maximum number of audits to which Seller is entitled pursuant to Section 3.6 herein, and may be
conducted by the

 

 

independent public accountants upon the provision of not less than thirty (30) days prior
written notice to Purchaser.

     3.6 Annual Audit Rights.

          3.6.1 Purchaser shall keep accurate books and records for purposes of documenting the amount
of the Net Sales and the calculation of Gross Margin with respect to each Product. Said books of
account shall be kept at Purchaser’s principal place of business. Upon at least thirty (30) days
prior written notice given on or before June 30th of each calendar year, Seller, at its expense,
shall have the right to have Seller’s independent public accountants (reasonably acceptable to
Purchaser) obtain access to Purchaser’s financial records for the previous calendar year, during
reasonable business hours solely for the purpose of verifying the amount of Net Sales and the
calculation of Gross Margin with respect to each Product for such previous calendar year;
provided, however, that this right may not be exercised more than once in any
calendar year. Purchaser agrees to reasonably cooperate with Seller’s independent public
accountants in the conduct of any such audit. Prior to disclosing the results of any such audit,
the auditor shall present Purchaser with a preliminary report of its findings and provide Purchaser
with an opportunity to respond to any questions raised or issues identified; provided, however,
that Seller shall receive the audit report as originally submitted by independent public
accountants along with Purchasers responses thereto to the extent such responses are given pursuant
to questions raised in an audit and to the extent that the responses are material to resolving the
audit. Seller shall solicit or receive only information relating to the accuracy of such
calculations and shall deliver to Purchaser a detailed written accountants’ report (setting forth,
among other things, the miscalculations, if any, identified by the audit) within thirty (30) days
of completion of the audit. If Seller does not submit a dispute in regards to the amount of Net
Sales or Gross Margin so audited within forty-five (45) days of Seller’s receipt of the audit
report, then the amount of Net Sales and Gross Margin as originally reported by Purchaser shall be
deemed to have been accepted and agreed to by Seller and shall be binding. Seller shall ensure
that Seller’s independent public accountants maintain the confidentiality of Purchaser’s
Confidential Information on terms no less restrictive than those set forth in Section 13. Such
accountants shall report to Seller only the results of the verification. Except in the event of a
bona fide dispute, any underpayment or overpayment of the Purchase Price due to a
miscalculation of such amount shall be paid within sixty (60) days after the delivery of the
detailed written accountants’ report to Purchaser. To the extent that the results of any audit
conducted by Seller discloses an underpayment of the Purchase Price by Purchaser to Seller by an
amount equal to or exceeding ten percent (10%) for the period in question, then the costs of the
audit shall be borne by Purchaser and Purchaser shall remit such costs within thirty (30) days of
the presentment of an invoice.

          3.6.2 Seller shall keep accurate books and records for purposes of documenting the Delivery
Price. Said books of account shall be kept at Seller’s principal place of business. Upon at least
thirty (30) days prior written notice given on or before June 30th of each calendar year,
Purchaser, at its expense, shall have the right to have Purchaser’s independent public accountants
(reasonably acceptable to Seller) obtain access to Seller’s financial records for the previous
calendar year, during reasonable business hours solely for the purpose of verifying the Delivery
Price for such previous calendar year; provided, however, that this right may not
be exercised more than once in any calendar year. Seller agrees to reasonably cooperate with
Purchaser’s independent public accountants in the conduct of any such audit. Prior to disclosing
the results of any such audit, the auditor shall present Seller with a preliminary report of its
findings and provide Seller with an opportunity to respond to any questions raised or issues
identified; provided, however, that Purchaser shall receive the audit report as originally
submitted by independent public accountants along with Seller responses thereto to the extent such
responses are given pursuant to questions raised in an audit and to the extent that the responses
are material to resolving the audit. Purchase shall solicit or

 

 

receive only information relating to the accuracy of such calculations and shall deliver to
Seller a detailed written accountants’ report (setting forth, among other things, the
miscalculations, if any, identified by the audit) within thirty (30) days of completion of the
audit. If Purchaser does not submit a dispute in regards to Delivery Price so audited within
forty-five (45) days of Purchaser’s receipt of the audit report, then the Delivery Price as
originally reported by Seller shall be deemed to have been accepted and agreed to by Purchaser and
shall be binding. Purchaser shall ensure that Purchaser’s independent public accountants maintain
the confidentiality of Seller’s Confidential Information on terms no less restrictive than those
set forth in Section 13. Such accountants shall report to Purchaser only the results of the
verification. Except in the event of a bona fide dispute, any underpayment or overpayment
of the Purchase Price due to a miscalculation of such amount shall be paid within sixty (60) days
after the delivery of the detailed written accountants’ report to Seller. To the extent that the
results of any audit conducted by Purchaser discloses an overpayment of the Delivery Price by
Purchaser to Seller by an amount equal to or exceeding ten percent (10%) for the period in
question, then the costs of the audit shall be borne by Seller and Seller shall remit such costs
within thirty (30) days of the presentment of an invoice.

SECTION 4

FORECASTS, ORDERS

     4.1 Forecasts and Orders. The initial forecast for the Products will be a 24-month
non-binding forecast of demand for each Product after the Effective Date for capacity planning
purposes, and is attached as Exhibit D. Purchaser shall submit to Seller a purchase order
for the initial six (6) months of the initial forecast within five (5) days of the Start Date of
this Agreement. Within five (5) days after the beginning of each calendar quarter during the Term
of this Agreement, Purchaser shall provide Seller with a written rolling forecast of Purchaser’s
expected requirements for the Products during the following twelve (12) months. The first six (6)
months of each such forecast shall be binding; and the amounts set forth for each of the following
two (2) calendar quarters shall constitute a non-binding, good faith estimate of the Product
requirements of Purchaser for such period for planning purposes only. Seller shall be required to
manufacture and deliver to Purchaser such quantities of Products as Purchaser orders in any
calendar quarter up to 125% of the quantity forecast for such calendar quarter in the immediately
preceding binding forecast. Seller shall use reasonable commercial efforts to manufacture, or have
manufactured, and deliver to Purchaser any quantities of Product Purchaser orders in excess of 125%
of the quantity forecasted for such calendar quarter, but shall be under no obligation to provide
to Purchaser any quantities of Product which exceed 125% of the quantity forecasted for such
calendar quarter. If Seller becomes aware of any circumstances that may cause Seller to default on
its obligation to deliver such quantities of Product as Purchaser orders or to fail to supply
quantities of Product in accordance with Purchaser’s forecasts for any calendar quarter, Seller
shall give Purchaser prompt written notice describing such circumstances, together with a proposed
course of action to remedy such failure. In the event of a significant change in market
conditions, significant new competitive factors and/or new key customer demands, the parties agree
to negotiate in good faith on appropriate changes to such forecasts.

     4.2 Orders. Purchaser shall submit binding written or electronic purchase orders for
Product (or by any other means agreed to in writing by the parties) to Seller, which shall be
placed at least one hundred eighty (180) days prior to the desired date of delivery, and which
binding orders shall comply with the binding forecasts set out in Section 4.1. Purchaser shall
have no minimum purchase requirements of Products during the Term of this Agreement. Purchase
orders shall be submitted by Purchaser to Seller in accordance with previously agreed upon delivery
mechanisms.

 

 

     4.3 Conflicts. To the extent of any conflict or inconsistency between this Agreement
and any purchase order, purchase order release, confirmation, acceptance or any similar document,
the terms of this Agreement shall govern.

     4.4 Capacity Allocation. In the event that Seller’s inability (including without
limitation any inability as a result of a Force Majeure Event) to meet firm orders, in whole or in
part, is due to a shortage of production capacity or common raw materials, Seller shall promptly
notify Purchaser in writing of such shortage of production capacity or common raw materials, and,
if possible, the date such shortage of production capacity or common raw materials is expected to
end. In such event, Seller shall allocate its available production capacity or raw materials to
the production of the Products in such proportion (expressed as a function of equipment utilized)
as the production equipment capacity or common raw materials actually utilized to meet orders for
the Products over the previous six (6) month period bears to total production equipment capacity
which is set up to manufacture the Products in such facility(ies) over that same period.

     4.5 Short Orders; Alternative Sources of Equivalent Products. In the event that
Seller fails (for any or no reason including without limitation any Force Majeure Event) to deliver
all or any portion of an order of Product to Purchaser in accordance with the terms of this
Agreement, Seller shall promptly notify in writing Purchaser of such fact. In addition to any
other rights and remedies available to Purchaser, Purchaser shall have the right, but not the
obligation, to modify any outstanding purchase order.

SECTION 5

SPECIFICATIONS

     5.1 Specifications.

          5.1.1 Attached as Exhibit A to this Agreement are the Specifications for each of the
Products. The Specifications for each Product shall not be changed except as permitted under this
Agreement.

          5.1.2 The attached Exhibit A also reflects the current Packaging for each Product.
The parties agree to cooperate in good faith with respect to any changes to the Packaging of the
Product with the Party requesting any changes to the Packaging bearing the development costs (e.g.
artwork or package design) of such changes.

     5.2 Changes.

          5.2.1 From time to time during the Term of this Agreement, either Party may submit to the
other written proposals for the adoption, implementation or development of any change, improvement
or modification to the Product. If such change is proposed by Seller, such change may be
implemented by Seller after consultation with Purchaser (but without requiring Purchaser’s consent)
so long as such change does not negatively impact the safety or efficacy of the Products, or
materially increase Purchaser’s liability with respect to the Products (any such change hereinafter
referred to as a “Material Change”). If such change is a Material Change, Seller shall not be
permitted to make such change without the prior written consent of Purchaser, such consent not to
be unreasonably withheld or delayed, and subject to the provisions of Sections 5.2.2 and 5.2.3
below. The Specifications shall be modified to reflect any such changes. In the event of any
change, Seller shall establish an appropriate qualification protocol, and Purchaser and Seller
shall determine an appropriate inventory level for the pre-change Product in order to cover
on-going requirements

 

 

during the qualification process. The foregoing shall not preclude Seller from implementing
process changes or other manufacturing related changes so long as such changes do not materially
alter the Specifications.

          5.2.2 In the event that Seller is required to change the Product Specifications pursuant to
applicable law, rule, or regulation or in response to the order of a governmental authority or
regulatory body, Seller shall promptly advise Purchaser in writing of any such change, as well as
any scheduling adjustments which may result from such change.

          5.2.3 In addition to the changes under Section 5.2.2, Purchaser shall also have the right to
request that a change be made to the Specifications at its expense and upon prior written notice to
Seller. Seller shall not be required to make any such change but shall consider Purchaser’s
request in good faith.

          5.2.4 In order for Purchaser to include in any Product Label or Labeling Purchaser Trademarks
or similar changes indicating Purchaser as the distributor of such Product, upon Purchaser’s
request, Seller shall provide Purchaser the Label artwork and text in electronic format. Purchaser
shall update such artwork and text to include Purchaser Trademarks and such other similar changes
as desired by Purchaser to indicate Purchaser as the distributor of such Product; provided that
Seller shall not be required to accept such changes if such changes do not comply with the NDA
under which the Product is to be sold and distributed and all applicable laws, rules and
regulations. Purchaser shall make all necessary arrangements, at its expense, to have such changed
Labels or Labeling printed and shall provide to Seller printer’s proofs for Seller’s review and
approval. Except with respect to the use of Purchaser’s Trademarks and supplied artwork, Seller
shall be responsible for ensuring the accuracy of all information contained on all Labels and
Labeling for the Products and for the compliance of all such Labels and Labeling with the NDA under
which such Products are to be sold and distributed and applicable law. In accordance with the
foregoing, Seller shall, within ten (10) business days of receipt of said printer’s proofs, provide
written notice to Purchaser of Seller’s approval of such proofs in the form submitted by Purchaser
or with such corrections thereto as included in Seller’s notice.

     5.3 Quality Requirements. The Seller shall, and shall cause any third party
manufacturer to, materially comply with the quality requirements set forth on Exhibit E
attached hereto (the “Quality Requirements”), with respect to the manufacture of the Product. To
the extent that any inconsistencies or conflicts exist between Exhibit E and this
Agreement, the stipulations and provisions in this Agreement shall prevail.

     5.4 Trademarks.

          5.4.1 All trademarks, trade names (if needed) and packaging graphics (collectively, the
“Purchaser Trademarks”) used by Purchaser in connection with the Products shall be chosen by
Purchaser in its discretion. Purchaser shall be responsible for any and all liabilities which may
arise from Purchaser’s use of the Purchaser Trademarks. Unless required by applicable law or
regulation or unless otherwise agreed to by the parties, Purchaser shall not use a trademark, trade
name, or copyright of Seller in connection with the distribution, marketing, promotion or sale of
the Products; to the extent that Purchaser believes that it shall or must use a trademark, trade
name or copyright of Seller, Seller shall be provided with advance notice of Purchaser’s intention
to do so and Seller must consent prior to any such use by Purchaser, such consent not to be
unreasonably withheld; provided, however, that Purchaser may use Seller’s trademarks, trade names
and copyright as contemplated under Section 14.1 and in Purchaser’s advertising and promotional
materials in order to, among other things, identify the Products as comparable to Seller’s brand
version product and to identify Seller as

 

 

the owner of Seller’s trademark used with its brand version product (e.g., “Oxandrolone
Tablets– Compare to Oxandrin®. Oxandrin® is a registered trademark of Savient Pharmaceuticals,
Inc.”). For the purpose of clarity, any use of Seller’s trademarks, trade names and/or copyright
pursuant hereto shall be made only with the prior written approval of Seller as to the specific use
thereby contemplated.

          5.4.2 Use of Purchaser Trademarks by Seller shall be solely for the purpose of preparing and
Packaging the Products for sale to Purchaser. Purchaser hereby grants a limited license on a
non-exclusive basis to Seller hereunder to use the Purchaser Trademarks in accordance with the
terms of this Agreement. Any and all Products supplied hereunder are for sale only to Purchaser
for distribution by Purchaser. Seller will not, at any time in any manner, represent that it has
ownership in any Purchaser Trademarks and acknowledges that it has no ownership interest in any
Purchaser Trademarks nor will Seller grant a sublicense to any third party to use such Purchaser
Trademarks. Upon expiration or earlier termination of this Agreement, Seller will cease and desist
use of any Purchaser Trademark in any way.

     5.5 Certificate of Analysis; Certificate of Compliance. Each shipment of the Products
to Purchaser shall be accompanied by a certificate of analysis prepared by an authorized
representative of Seller, including where applicable a third party manufacturer, confirming that
the Products in the shipment have been tested and shown to be in accordance with the Specifications
for such Products. Such certificates of analysis and certificates of compliance shall be
substantially in the form set forth in the Quality Requirements.

     5.6 Expiry Dating. Except for Products which comprise the Existing Inventory which
are addressed in Section 2.2.4, all Products shipped to Purchaser, at the time of shipment by
Seller, shall have no less than [ ** ] months expiry dating remaining for the 2.5mg
Product and no less than [ ** ] months expiry dating remaining for the 10mg Product.
Purchaser shall notify Seller in the event a Product has [ ** ] months or less dating
remaining, and within thirty (30) days of receipt of such notice Purchaser shall deduct from the
next quarterly payment owing to Seller [**] percent ([**]%) of the amount actually paid to Seller
for such Product. For all deliveries consisting of Existing Inventory, at the time of shipment by
Seller, such Products shall have no less than [ ** ] months expiry dating remaining. At
Seller’s option and sole expense, Purchaser shall (a) destroy such Product, or (b) return such
Product to Seller.

     5.7 Stability Testing. Seller shall maintain a stability testing program for the
Products and provide Purchaser with an annual product report thereon. In the event that any
results from such program could indicate that Product would not meet its expiry date, Seller shall
promptly notify Purchaser. At least one (1) batch per year of each Product (or its branded
equivalent), or as otherwise required by the NDA, shall be included in the stability program.

     5.8 Annual Report. Purchaser will supply distribution information and other required
information to Seller for the purposes of inclusion into the Annual Report to FDA and shall provide
such information in a timely manner so as to enable Seller to file the Annual Report in accordance
with applicable regulations. To the extent that Seller requests additional information from
Purchaser, Purchaser agrees to reasonably cooperate with Seller.

 

 

SECTION 6

TERM

     6.1 Term. The term of this Agreement shall commence on the Effective Date and remain
in effect for each Product hereunder for a period of ten (10) years from the Start Date for such
Product (the “Initial Term”), unless sooner terminated as expressly provided under the terms of
this Agreement. This Agreement will automatically renew for successive two-year periods following
the Initial Term (each, a “Renewal Term”), unless terminated prior to the expiry of the Initial
Term or any Renewal Term by either Party confirmed in writing and delivered at least twelve (12)
months prior to the expiration of the Initial Term or the Renewal Term to which it relates (the
Initial Term, together with any Renewal Terms, the “Term”). The distribution term for Product
shall become effective as of the date upon which Seller supplies and Purchaser actually receives
the Launch Quantities of Product (the “Distribution Term”) and shall remain in effect until the end
of the Term unless sooner terminated as expressly provided under the terms of this Agreement.

SECTION 7

TERMINATION

     7.1 Termination for Convenience. Each of Seller or Purchaser may terminate this
Agreement in its sole discretion (and without any liability to the other for such termination),
with respect to any Product, at any time on or after the fourth (4th) anniversary of the Start Date
of such Product upon no less than one (1) year prior written notice to the other, which prior
written notice, if any, shall be delivered on or after such fourth (4th) anniversary of such Start
Date.

     7.2 Breach. This Agreement may be terminated, on a Product by Product basis, prior to
the expiration of the Term, by either Party by giving written notice of its intent to terminate and
stating the grounds therefor if the other Party shall materially breach or materially fail in the
observance or performance of any representation, warranty, guarantee, covenant or obligation under
this Agreement. The Party receiving the default notice shall have sixty (60) days from the date of
receipt thereof to cure the breach or failure. If a breach is not curable within such sixty (60)
day period (other than a failure to supply Product in accordance with the terms of this Agreement),
then the non-performing Party shall have an additional sixty (60) days within which to cure such
breach so long as the non-performing Party is diligently working towards a remedy for such breach.
In the event such breach or failure is cured in accordance with the provisions of this Section 7.2,
the default notice shall be of no effect. In the event such breach or failure is not cured in
accordance with the provisions of this Section 7.2, then this Agreement shall terminate without the
requirement of the non-defaulting Party providing any additional notice to the defaulting Party.

     7.3 Insolvency, Etc. This Agreement may be terminated, prior to the expiration of the
Term, upon written notice by either Party: (i) in the event that the other Party hereto shall (1)
apply for or consent to the appointment of, or the taking of possession by, a receiver, custodian,
trustee or liquidator of itself or of all or a substantial part of its property, (2) make a general
assignment for the benefit of its creditors, (3) commence a voluntary case under the United States
Bankruptcy Code, as now or hereafter in effect (the “Bankruptcy Code”), (4) file a petition seeking
to take advantage of any law (the “Bankruptcy Laws”) relating to bankruptcy, insolvency,
reorganization, winding-up, or composition or readjustment of debts, (5) fail to controvert in a
timely and appropriate manner, or acquiesce in writing to, any petition filed against it in any
involuntary case under the Bankruptcy Code, or (6) take any corporate action for the purpose of
effecting any of the foregoing; or (ii) if a proceeding or case shall be commenced against the
other Party hereto in any court of competent

 

 

jurisdiction, seeking (1) its liquidation, reorganization, dissolution or winding-up, or the
composition or readjustment of its debts, (2) the appointment of a trustee, receiver, custodian,
liquidator or the like of the Party or of all or any substantial part of its assets, or (3) similar
relief under any Bankruptcy Laws, or an order, judgment or decree approving any of the foregoing
shall be entered and continue unstayed for a period of 60 days; or an order for relief against the
other Party hereto shall be entered in an involuntary case under the Bankruptcy Code.

     7.4 Failure to Supply. In the event that Seller supplies less than (i) [**] percent ([**]%) of the
aggregate quantity of Purchaser’s for Product for any two (2) out of three (3) consecutive calendar
months or (ii) [**] percent ([**]%) of the aggregate quantity of Purchaser’s for Product for any four (4) out of
six (6) consecutive calendar months, then Purchaser shall have the right to terminate this
Agreement immediately by providing written notice to Seller of such termination.

     7.5 Gross Margin Deficiency. If the aggregate Gross Margin in any period of three (3)
consecutive months is less than [**] percent ([**]%) of the aggregate Finished Product Price during such
three-month period (the amount by which the Gross Margin is less than [**] percent ([**]%) of the aggregate
Purchase Price is referred to herein as the “Gross Margin Deficiency”), then either Party
may thereafter terminate this Agreement with sixty (60) days prior written notice to the other
Party; provided, however, that in the event such termination notice is delivered by Seller such
notice shall be deemed rescinded and shall be of no force or effect if, within ten (10) business
days after receipt thereof, Purchaser pays to Seller an amount in cash equal to the Gross Margin
Deficiency. For avoidance of doubt, in the event that Purchaser provides notice of its intention to
terminate this Agreement pursuant to this Section 7.5, Purchaser shall nonetheless remain obligated
to purchase any outstanding binding order quantities.

     7.6 Other Termination. Purchaser shall have the right but not the obligation, to
terminate this Agreement with respect to any Product if the Start Date for such Product does not
occur on or before January 1, 2009. In the event Purchaser terminates the Agreement pursuant to
this Section, Seller shall promptly refund to Purchaser the amount paid to Seller for any quantity
of such Product on-hand at the time of such termination and Purchaser shall return all quantities
of Product on-hand to Seller.

     7.7 Transaction Event. Notwithstanding any other term of this Agreement, if, during
the Term, Purchaser enters into an agreement (an “Acquisition Agreement”) pursuant to which
it becomes an affiliate of an entity that develops, manufactures, markets or sells an Equivalent
Product, and provided that the primary purpose of the Acquisition Agreement was for something other
than acquiring rights to an Equivalent Product, Purchaser shall have the right to terminate this
Agreement with ninety (90) days’ prior written notice of such termination to the Seller. If
Purchaser exercises its rights under this Section 7.7, then beginning on the effective date of such
termination (the “Termination Date”), through the shorter of (a) the date that would have
been the natural expiration date of the Initial Term or the then current Renewal Term but for such
termination or (b) the date upon which the Agreement could have been terminated in accordance with
Section 7.1 hereof (i.e. one (1) year subsequent to the provision of notice following the fourth
(4th) anniversary of the Effective Date), (in either case, such period, the
“Remainder Period”), Purchaser shall:

          7.7.1 where there exists two complete calendar quarters of sales of Product in accordance with
this Agreement, make quarterly payments to Seller equal to [**]% of the average quarterly Gross
Margin of the two calendar quarters immediately preceding the quarter in which Purchaser provided
such notice of termination.

          7.7.2 in the event the Termination Date occurs prior to the completion of two (2) quarters of
sales of Product in accordance with this Agreement, amounts which are the product of the

 

 

following formula: (a) the average quarterly net
sales of Seller’s branded version of the
Product for the two (2) most recent quarters prior to the effective date of such termination, times
(b) the assumption on unit substitution rate of [**]
percent ([**]%), times (c) the assumption of captured market
share at [**] percent ([**]%), times (d) the pricing assumption of [**] percent ([**]%) of net selling price, less (e) cost of
goods sold for the average quarterly net sales of Seller’s branded version of the Product for the
two (2) most recent quarters prior to the effective date of such termination, the product thereof
times (f) [**] percent ([**]%);

          7.7.3 In both cases of 7.7.1 and 7.7.2 above, such amount shall be reduced by any amounts
earned by or paid to Seller by a third party in connection with the sale of the Product during the
Remainder Period.

The remedies set forth in this Section 7.7 set forth Seller’s sole and exclusive remedy in the
event Purchaser enters into an Acquisition Agreement.

     7.8 Intervening Equivalent Product Launch. In the event that an Equivalent Product
becomes commercially available, where such Equivalent Product is manufactured and sold by
unaffiliated third party or parties, prior to the receipt by Purchaser of the Launch Quantity of
Product, then Seller shall have the right to terminate this Agreement immediately upon the
provision of written notice to Purchaser; provided, however, that Seller shall promptly reimburse
Purchaser for any (i) payments made to Seller by Purchaser prior to such termination and (ii)
reasonable out-of-pocket costs incurred by Purchaser as a result of such termination.

     7.9 Effect of Termination.

          7.9.1 Subject to Section 7.9.3, upon expiration or termination of this Agreement, Seller shall
manufacture and ship, and Purchaser shall purchase from Seller in accordance with the terms and
conditions of this Agreement, any and all amounts of Products ordered by Purchaser hereunder prior
to the effective date of such expiration or termination.

          7.9.2 Termination of this Agreement for any reason shall be without prejudice to any rights
that have accrued to the benefit of either Party prior to such termination and shall not release
either Party hereto from any liability which at such time has already accrued or which thereafter
accrues from a breach or default prior to such expiration or termination, nor affect in any way the
survival of any other right, duty or obligation of either Party hereto which is expressly stated
elsewhere in this Agreement to survive such termination. In the case of a termination under
Section 7.2 above, the non-defaulting Party may pursue any remedy available in law or in equity
with respect to such breach, subject to the terms of Sections 15, 16 and 17.

          7.9.3 In the event that Purchaser terminates this Agreement pursuant to Section 7.2 for
Seller’s failure to cure a material breach of this Agreement, Purchaser shall not be obligated to
accept shipments of Product regardless of whether such Products were manufactured pursuant to Firm
Orders submitted by Purchaser. In the event that Seller terminates this Agreement pursuant to
Section 7.2 for Purchaser’s failure to cure a material breach of this Agreement, Seller shall have
the right to cease the manufacture Product and cancel all shipments of Product to Purchaser
regardless of whether such Products were manufactured pursuant to Firm Orders submitted by
Purchaser.

          7.9.4 For a period of five (5) years from the date of any termination or
expiration of the Agreement Purchaser shall, initially no later than sixty (60) days after the
six-month anniversary of the end of the calendar quarter within which the Agreement terminated or
expired, and quarterly thereafter, prepare and deliver to Seller a reasonably detailed report
(each, a “Gross Margin Report”), of the cumulative Gross Margin from the Effective Date through the
end of the period covered by the Gross Margin Report which reconciles (i) previously estimated
amounts of Gross Margin with (ii) actual

 

 

experience for the period covered by the Gross Margin Report (the difference, if any, the
“Reconciled Amount”). If the Gross Margin Report shows a positive adjustment to Gross Margin
Purchaser shall pay to Seller [**] percent ([**]%) of the Reconciled Amount within fifteen (15) days of Seller’s
receipt of the Gross Margin Report. If the Gross Margin Report shows a negative adjustment to
Gross Margin Seller shall pay to Purchaser [**] percent ([**]%) of the Reconciled Amount within fifteen (15) days
of Seller’s receipt of the Gross Margin Report.

     7.10 Survival. Sections 1, 3.4, 3.5, 5.7, 7.9, 7.10, 13, 15, 16, 17 and 18 as
well as any other provision which by its clear language is intended to survive, shall survive the
expiration or earlier termination of this Agreement in accordance with the respective terms
thereof.

SECTION 8

DELIVERY; INVENTORY

     8.1 Delivery. All charges for in-process storage, Packaging and bar coding are
included in the Purchase Price unless otherwise agreed to by the parties. Seller shall not be
responsible for warehousing finished goods for Purchaser and Seller shall ship all finished goods
to Purchaser FCA (Incoterms 2000) Seller’s premises. All shipments must be accompanied by a
packing slip that describes the articles, states the purchase order number and shows the shipment’s
destination. Deliveries of Products shall be made in accordance with the delivery schedule set
forth in the purchase orders provided in compliance with Section 4.2. For the avoidance of doubt,
Seller shall not make deliveries of Products in advance of the delivery schedule set forth in such
purchase orders without the prior written approval of Purchaser.

     8.2 Shipment. The risk of loss with respect to Products shall be with Purchaser in
accordance with the relevant provisions associated with the FCA (Incoterms 2000) delivery terms.
Seller will pack all Products ordered hereunder in a manner suitable for shipment and sufficient to
enable the Products to withstand the effects of shipping, including handling during loading and
unloading. Purchaser shall use its Commercially Reasonable Efforts to notify Seller within one (1)
business day of Purchaser’s discovery of any lost or stolen goods to facilitate Seller’s
notification of the FDA.

SECTION 9

DEFECTIVE PRODUCTS

     9.1 Rejection and Cure. If a shipment of Product or any portion thereof has a Patent
Defect or Latent Defect, then Purchaser shall have the right to reject such nonconforming shipment
of Product or the nonconforming portion thereof, as the case may be, in accordance with the
following:

          9.1.1 Purchaser shall give written notice to Seller of its rejection hereunder, within thirty
(30) days after Purchaser’s receipt of shipment of any Product containing a Patent Defect,
specifying the grounds for such rejection. After receipt of such notice from Purchaser, Seller
shall be permitted to analyze any Product rejected by Purchaser for nonconformity, and to present
its findings with respect to such Product to Purchaser. If the parties cannot agree on whether the
Product in question is nonconforming, an independent laboratory, reasonably acceptable to both
parties and at a cost equally shared by both parties, shall analyze both Purchaser’s and Seller’s
samples of Product in question, and the definitive results of such laboratory shall be binding. If
the shipment of Product in

 

 

question is determined to be nonconforming, such nonconforming Product shall be held for
Seller’s disposition, or shall be returned to Seller, in each case at Seller’s expense, as directed
by Seller. Seller shall use its Commercially Reasonable Efforts to replace each nonconforming
shipment of Product, or the nonconforming portion thereof, with conforming Product as soon as
reasonably practicable after receipt of notice of rejection thereof, and in any event shall do so
within thirty (30) days after receipt of notice of rejection thereof. If and to the extent that the
nominated independent laboratory determines that the rejected Product is conforming, and to the
extent that Seller has replaced such rejected Product with additional Product, then Purchaser shall
be responsible for the Delivery Price for both the allegedly nonconforming Product and for the
replacement Product.

          9.1.2 As soon as either Party becomes aware of a Latent Defect in any Product lot, it shall
immediately notify the other Party and the batch involved, at Purchaser’s election, shall be deemed
rejected as of the date of such notice. Seller shall refund all moneys paid for the shipment of
Product involved and shall reimburse Purchaser for its costs of accepting returns from its
customers and shall be responsible for all costs reasonably incurred by Purchaser in recalling
Product that have Latent Defects.

SECTION 10

REGULATORY MATTERS

     10.1 Reporting; Etc. Purchaser shall have the responsibility in the Territory for
complying with all regulatory filings, reporting requirements and other matters which relate solely
to Purchaser’s acting as a distributor of the Product in the Territory. All other regulatory
reporting matters (including adverse event and Product complaint reporting) shall be Seller’s
responsibility. Each of Seller and Purchaser shall notify the other of receipt of any report(s) of
adverse events or product complaints pursuant to Exhibit C. Exhibit C sets forth
additional details with respect to the handling of adverse event reporting.

     10.2 FDA Communications. Purchaser and Seller agree to promptly notify the other
Party in the event they receive any communication or notice from the FDA with respect to the
Products, and each Party shall promptly provide a copy of such communications to the other. The
parties shall cooperate in good faith in responding to any such FDA inquiry or in making any report
to the FDA with respect to the Products, but in all cases Seller shall have final authority for
regulatory decisions concerning the Products and responsibility for all communications with the
FDA. Notwithstanding the foregoing, to the extent any such communication or decision relates
solely to the Products (and not Seller’s branded version of the Products), then Seller shall not
make such communication or decision without the prior written consent of Purchaser, such consent
not to be unreasonably withheld or delayed.

     10.3 Audits. Purchaser shall have the right, at Purchaser’s sole expense, to audit
Seller, during normal business hours, upon written notice to Seller in accordance with the terms of
the Quality Requirements set forth in Exhibit E hereto, and Seller’s facilities and
documents, which relate to the manufacture, processing, Packaging, testing or storage of a Product.
Purchaser shall have the right to conduct such audit no more than one (1) time per calendar year;
provided, however, that in the event Purchaser has identified any substantive,
material quality issue, then Purchaser shall be entitled to such reasonable number of additional
follow-up audits as may be needed to confirm the steps taken to rectify such issue. In no event
shall an audit of a particular facility exceed two (2) days in duration or involve more than three
(3) representatives of Purchaser unless mutually agreed in writing by the parties. Such
inspections and audits hereunder shall be carried out in a manner that does not unreasonably
interfere with the normal conduct of business. Any such representatives shall

 

 

be reasonably qualified in terms of auditing skill to conduct audits and shall comply with
Seller’s normal company policies and with security and safety regulations. Any third party
representatives conducting such audits shall execute a written agreement to maintain in confidence
all information obtained during the course of any such audit except for disclosure to Purchaser.
In addition, Seller shall audit any unaffiliated third party manufacturer for compliance on a
periodic schedule and to the extent permitted pursuant to the terms of any agreement between Seller
and such unaffiliated third party manufacturer, shall promptly provide Purchaser a copy of such
audit report. Seller shall use best efforts to obtain the consent of any third party manufacturer
for Purchaser to participate in, or to conduct on its own, audits as contemplated in this section.
Notwithstanding the foregoing, any failure by Seller to obtain such third party consent shall not
be considered a breach of this Agreement.

     10.4 Audit Feedback. Within thirty (30) days of completing any audit hereunder,
Purchaser shall submit to Seller (and the third party manufacturer, if applicable) a written
report outlining its findings and/or observations from any such audit. If deficiencies are
discovered during an audit that could, in Purchaser’s opinion, prevent Seller or the third party
manufacturer from satisfying the requirements of cGMP, and Seller or the third party manufacturer
in good faith disputes the observations or conclusions of Purchaser, then the Parties shall
promptly enter into good faith discussions to resolve their differences. If the Parties fail to
resolve their differences within thirty (30) days after receipt of the audit report, then the
parties shall resolve their differences in accordance with Section 17.1 hereto; provided,
however, that Purchaser shall not be prohibited from taking any action applicable to
Purchaser that it is required to take under applicable law. If Seller (or the third party
manufacturer, as the case may be) does not dispute the observations made during any audit it shall
use its Commercially Reasonable Efforts to correct those deficiencies at its own cost, and shall
notify Purchaser in writing when those deficiencies are corrected.

     10.5 Recalls. Seller and Purchaser each shall notify the other promptly if any batch
of Product purchased by Purchaser pursuant to this Agreement is the subject of a recall or market
withdrawal, and the Parties shall cooperate in the handling and disposition of such recall or
market withdrawal; provided, however, in the event of a disagreement as to any matters related to
such recall or market withdrawal, other than the determination of who shall bear the costs as set
forth below, Seller shall have the final authority with respect to any Product recall.
Notwithstanding the foregoing, Purchaser shall not be restricted from taking any action which
Purchaser believes in good faith after consultation with its legal counsel is required by law or
regulation; provided, however, that nothing in this section shall relieve Purchaser from any
liability associated with a Purchaser initiated voluntary recall of Product that is subsequently
determined, in accordance with the provisions of Section 17.2, to have been in error. Purchaser
shall bear the cost of all recall or market withdrawals of Product purchased by Purchaser pursuant
to this Agreement unless such recall or market withdrawal shall have been the result of (i)
Seller’s failure to manufacture, Package or Label the Product in accordance with the requirements
of this Agreement, or the failure of the Product to meet the Specifications, or (ii) Seller’s
breach of any of its obligations or warranties set forth in this Agreement, in which case Seller
shall bear the cost of such recall or market withdrawal. Purchaser shall maintain records of all
sales of Product and customers sufficient to adequately administer a recall or market withdrawal
for the longer of three (3) years after the date of the last sale of the Product by Purchaser or
the period required by applicable law. Purchaser shall, in all events and regardless of who bears
the cost, be responsible for administrating the physical aspects of any recalls or market
withdrawals with respect to the Products. For the avoidance of doubt, Product returns relating to
a recall or market withdrawal will be deducted from Net Sales.

 

 

     10.6 Batch Records. Batch records, including information relating to the
manufacturing, Packaging, and quality control testing and analysis for each lot of finished Product
produced hereunder, will be prepared in accordance with Seller’s standard operating procedures.
Batch records and all other records relating to production hereunder shall be retained by Seller
for such period of time as is required under applicable rules and regulations of the FDA. In the
event (i) Seller receives a regulatory letter or comments from any federal agency in connection
with its manufacture of the Product or the facility where the Product is manufactured requiring a
response or action by Seller, or the third party manufacturer, including, but not limited to,
receipt of a Form 483 (Inspectional Observations) or a “Warning Letter,” or (ii) any batch of
Product purchased by Purchaser pursuant to this Agreement is the subject of a recall or market
withdrawal (each of (i) and (ii) a “For Cause Incident”), promptly following Purchaser’s prior
written request therefore, Seller make available to Purchaser, at Seller’s premises during business
hours, a complete copy of an executed batch record for each SKU of Product associated with such For
Cause Incident. Additionally, Seller shall, upon Purchaser’s written request in connection with
any Audit, and to the extent applicable, make available for review by Purchaser during the course
of such Audit, updates to the process validation report and equipment cleaning validation for each
Product. All records made available to Purchaser hereunder shall be considered highly confidential
materials of Seller and may not be used by Purchaser for any purpose other than the furtherance of
the purposes of this Agreement.

     10.7 Adverse Events. The parties respective obligations with respect to Product
adverse event reporting are set forth in Exhibit C attached hereto.

     10.8 Medical Information Inquiries. All requests for medical information for Product
will be directed back to the Seller for follow up. After the Effective Date, the Medical Affairs
groups of Purchaser and Seller shall discuss and agree upon procedures for the handling and
transfer of the inquiries.

     10.9 Labeling and Packaging. The parties’ respective responsibilities with respect to
Labeling and Packaging are set forth on Exhibit F attached hereto.

     10.10 Inspections.

          10.10.1 In the event Seller’s, or a third party manufacturer’s, manufacturing, packaging,
testing or storage facility producing the Products hereunder is inspected by representatives of any
federal agency in connection with Seller’s, or a third party manufacturer’s, manufacture,
packaging, testing or storage of a Product, Seller shall notify Purchaser promptly upon learning of
such inspection, and shall promptly supply Purchaser with copies of any correspondence or portions
of correspondence which relate to such Product or the facility where such Product is manufactured;
provided, however, that Seller shall not be obligated to provide any documents which would violate
any agreement existing between Seller and any third party manufacturer. In the event Seller, or a
third party manufacturer, receives any regulatory letter or comments from any federal agency in
connection with its manufacture of the Product or the facility where the Product is manufactured
requiring a response or action by Seller, or the third party manufacturer, including, but not
limited to, receipt of a Form 483 (Inspectional Observations) or a “Warning Letter,” (a) Seller
shall promptly provide Purchaser with a copy of such regulatory letter or comments, and (b)
Purchaser will provide Seller with any data or information reasonably required by Seller in
preparing any response relating to Seller’s manufacture of the Product, and Purchaser will
cooperate with Seller in preparing such response, and Seller will promptly provide Purchaser with a
copy of any such response; provided, however, that Seller shall not be obligated to provide any
documents which would violate any agreement existing between Seller and any third party
manufacturer.

 

 

          10.10.2 In the event Purchaser is inspected or receives a regulatory letter or comments from
any federal agency in connection to the distribution of the Products, Purchaser shall promptly
notify Seller upon learning of such inspection or receiving such documentation. Seller may
participate in that portion of such inspection relating to such Product (and shall be required to
participate if reasonably requested by Purchaser). If either Seller or Purchaser requests Seller
to participate as described above, Seller and Purchaser shall mutually agree on the response with
respect to such Product and Purchaser shall be responsible for submitting any such responses to the
regulatory authorities. Seller will promptly provide Purchaser with all data or information
reasonably required by Purchaser in preparing for any such inspection or any response relating to
the Products, and Purchaser will promptly provide Seller with a copy of any such response.

     10.11 Cooperation. Seller shall provide reasonable assistance to Purchaser in its
preparation and filing with appropriate regulatory agencies (both federal and state agencies
related to reimbursement and health care insurance) of filings required for the marketing, Labeling
(if applicable), Packaging (if applicable) and distribution of the Products in the Territory by
Purchaser. Seller and Purchaser shall work together in good faith to develop such necessary
regulatory strategies which may be required for purposes of this Agreement, and to allow the
Products to be listed on applicable formularies and other drug listings as reasonably requested by
Purchaser, and making any applicable filings or registrations to allow the Products to be included
on such formularies or listings, including, without limitation, Medicare and Medicaid. In
addition, Seller shall promptly provide to Purchaser copies (in electronic format if available) of
those materials which Seller currently uses to respond to inquiries regarding the Products from
consumers and health care professionals.

SECTION 11

FORCE MAJEURE

     11.1 Force Majeure Events. If either Party is prevented from performing any of its
obligations hereunder (except for any financial payments due hereunder) due to any cause which is
beyond the non-performing Party’s reasonable control, including fire, explosion, flood, or other
acts of God; acts, regulations, or laws of any government; court injunction or other court order;
war or civil commotion; strike, lock-out or labor disturbances; or failure of public utilities or
common carriers (a “Force Majeure Event”), such non-performing Party shall not be liable for breach
of this Agreement with respect to such non-performance to the extent any such non-performance is
due to a Force Majeure Event. Except as set forth below, such non-performance will be excused for
as long as such Force Majeure event shall be continuing, provided that the non-performing Party
gives immediate written notice to the other Party of the Force Majeure Event. Such non-performing
Party shall exercise all reasonable efforts to eliminate the Force Majeure Event and to resume
performance of its affected obligations as soon as practicable. In the event such Force Majeure
Event continues unabated for a period of ninety (90) days or longer, then the Party which is not
subject to such Force Majeure Event may terminate this Agreement in its entirety or with respect to
the Products affected by the Force Majeure Event upon thirty (30) days prior written notice to the
other Party.

SECTION 12

INSURANCE

     12.1 Insurance. Each Party agrees to procure and maintain in full force and effect
during the Term and for a period of three (3) years thereafter, at its sole cost and expense
Products Liability, General Liability and Property Damage insurance with a combined single limit of
not less than $10,000,000 per occurrence and $20,000,000 in the aggregate annually, which insurance shall name
the other Party as an

 

 

additional insured. Each Party shall, on request, provide to the other Party copies of a
certificate of coverage or other written evidence reasonably satisfactory to such Party of such
insurance coverage. Either Party may substitute a program of self-insurance for all or part of the
third party insurance required hereunder.

SECTION 13

CONFIDENTIALITY

     13.1 Confidentiality. As used herein, “Confidential Information” shall include all
confidential or proprietary information given to one Party by the other Party, or otherwise
acquired by such Party in its performance of this Agreement, relating to such other Party or any of
its Affiliates, including information regarding any of the products of such other Party or any of
its Affiliates, information regarding its advertising, distribution, marketing or strategic plans
or information regarding its costs, productivity or technological advances. Neither Party shall
use or disclose to third parties any Confidential Information of the other (except to comply with
its obligations under this Agreement) and each Party shall insure that its and its Affiliates’
employees, officers, representatives and agents shall not use or disclose to third parties any
Confidential Information and upon the termination of this Agreement shall return to the other or
destroy all Confidential Information in written form, provided, however, that such Party may retain
one (1) copy of such Confidential Information to ensure compliance with the terms of this
Agreement. Confidential Information shall not include information that (i) was already known to
receiving Party at the time of its receipt thereof or is independently developed by receiving
Party, as evidenced by its written records, (ii) is disclosed to receiving Party after its receipt
thereof by a third party who has a right to make such disclosure without violating any obligation
of confidentiality, (iii) is or becomes part of the public domain through no fault of receiving
Party or (iv) is independently developed by a Party as evidenced by contemporaneous written
documentation. The obligations of confidentiality set out above shall survive termination or
expiration of this Agreement for a period of three (3) years.

SECTION 14

PUBLIC ANNOUNCEMENTS

     14.1 Public Announcements. Neither Party shall make any publicity releases concerning
the terms of this Agreement without the prior written approval of the other Party, which approval
shall not unreasonably be withheld or delayed. Notwithstanding the foregoing, (a) the parties
agree that the form of the Press Release, attached hereto as Exhibit G, shall be published
on the Start Date, (b) either Party may publish and republish, in whole or in part, any publicity
release and/or make any statement to communication media, financial analysts or others that is the
same or substantially similar to a publicity release or statement that has been previously approved
by the other Party in accordance with the terms hereof, without obtaining the prior approval of
such other Party, and (c) either Party may upon notice to the other make any disclosure in filings
with regulatory agencies or exchanges or as required by law or applicable court order; provided
that the other Party shall have the opportunity to consult on such disclosures and filings.

 

 

SECTION 15

REPRESENTATIONS AND WARRANTIES

          15.1 Seller Warranties. Seller represents and warrants to Purchaser as follows:

          15.1.1 all Product supplied in connection with this Agreement shall be manufactured and
provided in accordance and conformity with the Specifications and at time of delivery will be free
from material defects in materials and workmanship;

          15.1.2 all Labeling shall be performed so that the Product shall not be misbranded under any
applicable laws, rules and regulations.

          15.1.3 it shall comply with all present and future statutes, laws, ordinances and regulations
relating to the manufacture and supply of the Products being provided hereunder, including, without
limitation, those enforced by the United States Food and Drug Administration (including compliance
with good manufacturing practices);

          15.1.4 to the best of Seller’s knowledge, the manufacture of the Products by Seller does not
infringe any patent of any third party or constitute a misappropriation of the trade secrets or
other intellectual property rights of any third party; and

          15.1.5 to the best of Seller’s knowledge, neither Seller nor its Affiliates or their employees
have ever been (i) convicted of a crime for which a person can be debarred under Section 306(a) or
306(b) of the Generic Drug Enforcement Act of 1992 or under 42 U.S.C. Section 1320-7 or (ii)
sanctioned by, suspended, excluded or otherwise ineligible to participate in any federal health
care program, including Medicare and Medicaid or in federal procurement or non-procurement
programs.

     15.2 Purchaser Warranties. Purchaser represents and warrants to Seller as follows:

          15.2.1 Purchaser shall discharge its obligations pursuant to this Agreement in accordance with
all applicable laws, rules and regulations;

          15.2.2 Purchaser is the owner of all Purchaser Trademarks and has the right to license to
Seller the Purchaser Trademarks for use in accordance with the terms of this Agreement;

          15.2.3 Purchaser shall avoid misleading or deceptive marketing practices in its distribution,
marketing, promotion or sale of the Products hereunder;

          15.2.4 Purchaser shall use Commercially Reasonable Efforts to actively promote the
distribution and sale of the Product within the Territory so as to maximize Net Sales therein; and

          15.2.5 Purchase shall maintain the Product, pending sale to its customers, in a facility that
is properly equipped (including temperature and humidity control) to store such Product.

     15.3 Execution and Performance of Agreement. Seller and Purchaser each represents to
the other that it has full right, power and authority to enter into and perform its obligations
under this Agreement. Seller and Purchaser each further represents and warrants to the other that
the performance of its obligations under this Agreement will not result in a violation or breach
of, and will not conflict with or constitute a default under any agreement, contract, commitment or
obligation to which such Party or any of its Affiliates is a Party or by which it is bound.

 

 

     15.4 EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, THERE ARE NO OTHER REPRESENTATIONS OR
WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, MADE OR GIVEN BY EITHER PARTY HEREUNDER, INCLUDING,
WITHOUT LIMITATION, ANY WARRANTY AS TO MERCHANTABILITY, NONINFRINGEMENT OR FITNESS FOR ANY
PARTICULAR PURPOSE.

SECTION 16

INDEMNIFICATION

     16.1 Indemnification by Seller. Seller shall indemnify and hold harmless Purchaser
(and its Affiliates) from and against any and all damages, liabilities, claims, costs, charges,
judgments and expenses (including reasonable attorneys’ fees) (collectively “Damages”) that may be
sustained, suffered or incurred by Purchaser (or its Affiliates), that result or arise in
connection with (i) any actual or alleged death or bodily injury to any individual arising out of
the use of the Product sold by Purchaser, including any claim based on failure to warn, design
defect, product defect, strict liability in tort, or otherwise, (ii) the breach by Seller of any
warranty, representation, covenant or agreement made by Seller in this Agreement, (iii) the design,
manufacture, Labeling, Packaging or supply of the Products by Seller or its Affiliates hereunder,
or (iv) the (negligent or intentional misconduct of Seller or, to the extent related to any action
of an Affiliate in connection with this Agreement, its Affiliates; but excluding in each case above
those matters for which Purchaser is obligated to indemnify Seller pursuant to Section 16.2 and
except to the extent that any such Damages are a result of the negligent or intentional actions or
omissions on the part of Purchaser.

     16.2 Indemnification by Purchaser. Purchaser shall indemnify and hold harmless Seller
(and its Affiliates) from and against any and all Damages, that may be sustained, suffered or
incurred by Seller (or its Affiliates) that result or arise in connection with (i) the breach by
Purchaser of any warranty, representation, covenant or agreement made by Purchaser in this
Agreement or (ii) the distribution, marketing, or sale of the Products by Purchaser following the
Seller’s delivery of the Products to Purchaser, or (iii) the negligent or intentional misconduct of
Purchaser, or to the extent related to any action of an Affiliate in connection with this
Agreement, its Affiliates, but excluding in each case above those matters for which Seller is
obligated to indemnify Purchaser pursuant to Section 16.1 and except to the extent that any such
Damages are a result of the negligent or intentional actions or omissions on the part of Seller.

     16.3 Claims. Each indemnified Party agrees to give the indemnifying Party prompt
written notice of any matter upon which such indemnified Party intends to base a claim for
indemnification (an “Indemnity Claim”) under this Section 16. The indemnifying Party shall have
the right to participate jointly with the indemnified Party in the indemnified Party’s defense,
settlement or other disposition of any Indemnity Claim. With respect to any Indemnity Claim
relating solely to the payment of money damages and which could not result in the indemnified
Party’s becoming subject to injunctive or other equitable relief or otherwise adversely affect the
business of the indemnified Party in any manner, and as to which the indemnifying Party shall have
acknowledged in writing the obligation to indemnify the indemnified Party hereunder, the
indemnifying Party shall have the sole right to defend, settle or otherwise dispose of such
Indemnity Claim, on such terms as the indemnifying Party, in its sole discretion, shall deem
appropriate; provided that the indemnifying Party shall provide reasonable evidence of its ability
to pay any damages claimed and with respect to any such settlement shall obtain the written release
of the indemnified Party from the Indemnity Claim. The indemnifying Party shall obtain the written
consent of the indemnified Party, such consent not to be unreasonably withheld, prior to ceasing to
defend, settling or otherwise disposing of any Indemnity Claim if as a result thereof the
indemnified

 

 

Party would become subject to injunctive or other equitable relief or the business of the
indemnified Party would be adversely affected in any manner.

SECTION 17

DISPUTE RESOLUTION

     17.1 Executive Resolution. If any dispute arises between the parties relating to the
interpretation, breach or performance of this Agreement or the grounds for the termination thereof,
the parties agree that before submitting such dispute to arbitration as set forth in Section 17.2
below, the Presidents (or a designee of senior management level) of each Party shall, for a period
of thirty (30) days after such dispute is formally submitted to either of such Presidents in
writing, attempt in good faith to negotiate a resolution of the dispute. The foregoing shall not
be interpreted to preclude either Party from seeking and obtaining from the appropriate court
provisional remedies such as attachment, preliminary injunction, replevin, etc. to avoid
irreparable harm, maintain the status quo, or preserve the subject matter of the
dispute.

     17.2 Arbitration. All disputes relating in any way to this Agreement shall be
resolved exclusively through arbitration conducted in accordance with the Commercial Arbitration
Rule of the American Arbitration Association as then in effect. The arbitration hearing shall be
held in the English language in New York, NY (U.S.) in accordance with the substantive law of the
State of New York (without reference to New York’s choice of law rules) and shall be before a
single arbitrator selected by the parties in accordance with the Commercial Arbitration Rule of the
American Arbitration Association pursuant to its rules on selection of arbitrators. Any arbitrator
selected shall have reasonable experience as an arbitrator of disputes between entities in the
pharmaceutical industry. The arbitrator shall render a formal, binding non-appealable resolution
and award on each issue as expeditiously as possible but not more than ten (10) business days after
the hearing. The prevailing Party in the arbitration shall be entitled to reimbursement of its
reasonable attorneys’ fees, and the parties shall use all reasonable efforts to keep arbitration
costs to a minimum. The relevant cure periods for breach under this Agreement shall toll while
either Party pursues in good faith a resolution to a dispute under this Section 17.2.

SECTION 18

MISCELLANEOUS

     18.1 Relationship of the Parties. The relationship of Purchaser and Seller
established by this Agreement is that of independent contractors, and nothing contained herein
shall be construed to (i) give either Party any right or authority to create or assume any
obligation of any kind on behalf of the other or (ii) constitute the parties as partners, joint
venturers, co-owners or otherwise as participants in a joint or common undertaking.

     18.2 Third Party Rights. Nothing in this Agreement shall be deemed to create any
third party beneficiary rights in or on behalf of any other person.

     18.3 Entire Agreement. It is the mutual desire and intent of the parties to provide
certainty as to their respective future rights and remedies against each other by defining the
extent of their mutual undertakings as provided herein. The parties have, in this Agreement
(including the Exhibits hereto), incorporated all representations, warranties, covenants,
commitments and understandings on which they have relied in entering into this Agreement, and,
except as provided for herein, neither Party makes any covenant or other commitment to the other
concerning its future

 

 

action. Accordingly, this Agreement and the Exhibits hereto (i) constitute the entire
agreement and understanding between the parties with respect to the subject matter hereof and there
are no promises, representations, conditions, provisions or terms related thereto other than those
set forth in this Agreement and (ii) supersede all previous understandings, agreements and
representations between the parties, written or oral. No modification, change or amendment to this
Agreement shall be effective unless in writing signed by each of the parties hereto.

     18.4 Headings. The Article and Section headings contained in this Agreement are for
reference purposes only and shall not affect in any way the meaning and interpretation of this
Agreement.

     18.5 Notices. All notices and other communications hereunder shall be in writing.
All notices hereunder of an Indemnity Claim, a Force Majeure Event, default or breach hereunder,
or, if applicable, termination or renewal of the term hereof, or any other notice of any event or
development material to this Agreement taken as a whole, shall be delivered personally, or sent by
national overnight delivery service or postage pre-paid registered or certified U.S. mail, and
shall be deemed given: when delivered, if by personal delivery or overnight delivery service; or
if so sent by U.S. mail, five business days after deposit in the mail, and shall be addressed:

	 	 	 	 	 
	 

	 	If to Seller:
	 	Watson Pharma, Inc.
	 

	 	 	 	360 Mount Kemble Avenue
	 

	 	 	 	Morristown, NJ, 07962
	 

	 	 	 	Attention: President and Chief Operating Officer
	 

	 	 	 	Telephone: (973) 355-8550
	 

	 	 	 	Fax: (973) 355-8580
	 
	 	 	 	 
	 

	 	With a copy to:
	 	Watson Pharmaceuticals, Inc.
	 

	 	 	 	311 Bonnie Circle
	 

	 	 	 	Corona, CA 92880-2882
	 

	 	 	 	Attention: General Counsel
	 

	 	 	 	Telephone: (951) 493-5925
	 

	 	 	 	Fax: (951) 493-5821
	 
	 	 	 	 
	 

	 	If to Seller:
	 	Savient Pharmaceuticals, Inc.
	 

	 	 	 	One Tower Center
	 

	 	 	 	Fourteenth Floor
	 

	 	 	 	East Brunswick, New Jersey 08816
	 

	 	 	 	Attention: President
	 

	 	 	 	Telephone: (732) 418-4705
	 

	 	 	 	Fax: (732) 418-3687
	 
	 	 	 	 
	 

	 	With a copy to:
	 	Savient Pharmaceuticals, Inc.
	 

	 	 	 	Attn: General Counsel
	 

	 	 	 	One Tower Center, 14th Floor
	 

	 	 	 	East Brunswick, NJ 08816

or to such other place as either Party may designate by written notice to the other in accordance
with the terms hereof.

     18.6 Failure to Exercise. The failure of either Party to enforce at any time for any
period any provision hereof shall not be construed to be a waiver of such provision or of the right
of such

 

 

Party thereafter to enforce each such provision, nor shall any single or partial exercise of
any right or remedy hereunder preclude any other or further exercise thereof or the exercise of any
other right or remedy. Remedies provided herein are cumulative and not exclusive of any remedies
provided at law.

     18.7 Assignment. This Agreement may not be assigned by either Party without the prior
written consent of the other, such consent not to be unreasonably withheld, except that either
Party may assign its rights and/or obligations hereunder to (i) any of its Affiliates, or (ii) any
party or entity which acquires substantially all of the business or assets of such Party to which
this Agreement relates if such Party guarantees the performance of the acquiring party and the
acquiring party expressly assumes the assigning Party’s obligations hereunder.

     18.8 Severability. In the event that any one or more of the provisions (or any part
thereof) contained in this Agreement or in any other instrument referred to herein, shall, for any
reason, be held to be invalid, illegal or unenforceable in any respect pursuant to a final,
non-appealable decision in accordance with the dispute resolution provisions set forth in Section
17, then to the maximum extent permitted by law, such invalidity, illegality or unenforceability
shall not affect any other provision of this Agreement or any other such instrument. Any term or
provision of this Agreement which is so held to be invalid, illegal or unenforceable in any
jurisdiction shall, to the extent the economic benefits conferred by this Agreement to both parties
remain substantially unimpaired, not affect the validity, legality or enforceability of any of the
terms or provisions of this Agreement in any other jurisdiction.

     18.9 Counterparts. This Agreement may be executed in one or more counterparts, each
of which shall be deemed an original, but all of which together shall constitute one and the same
instrument.

     18.10 Expenses. Each Party shall pay all of its own fees and expenses (including all
legal, accounting and other advisory fees) incurred in connection with the negotiation and
execution of this Agreement and the arrangements contemplated hereby.

     18.11 Governing Law. This Agreement shall be governed by the laws of the State of
Delaware without giving effect to any conflict of law provisions or principles.

     18.12 Limitation of Liability. EXCEPT FOR THE PARTIES’ INDEMNIFICATION OBLIGATIONS
UNDER SECTION 16.1 AND 16.2, UNDER NO CIRCUMSTANCES WILL EITHER PARTY BE LIABLE FOR
ANY SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE OR CONSEQUENTIAL DAMAGES, COSTS OR EXPENSES (INCLUDING,
BUT NOT LIMITED TO, LOST PROFITS, LOST REVENUES AND/OR LOST SAVINGS), ARISING UNDER THIS AGREEMENT
OR CONCERNING ANY PRODUCTS, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES,
COSTS OR EXPENSES.

[Signature page follows]

 

 

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their duly
authorized respective representatives as of the day and year first above written.

	 	 	 	 	 
	 	WATSON PHARMA, INC.

 	 
	 	By:  	/s/ Andrew S. Boyer
 	 
	 	 	Name:  	Andrew S. Boyer 	 
	 	 	Title:  	VP Sales and Marketing 	 
	 

	 	 	 	 	 
	 	SAVIENT PHARMACEUTICALS, INC.

 	 
	 	By:  	/s/ Christopher Clement
 	 
	 	 	Name:  	Christopher Clement 	 
	 	 	Title:  	President & CEO 	 
	 

 

 

LIST OF EXHIBITS

A. Product, Specifications and Packaging

B. Initial Finished Product Prices

C. Adverse Event Reporting Procedures

D. Initial Purchase Order Forecast

E. Quality Requirements

F. Form of Press Release

 

EXHIBIT A

Product, Specifications and Packaging

Oxandrolone Tablets USP, 2.5mg and 10.0 mg tablets (the “Product”)

[**]

A-1

 

EXHIBIT B

Finished Product Prices

     The initial Finished Product Price with respect to the launch quantities of each Product shall
be as provided below:

	 	 	 	 	 
	NDC	 	Description	 	Finished Product Price
	[**]

	 	2.5 mg (100) ct
	 	$[**]/bottle
	[**]

	 	10.0 mg (60) ct
	 	$[**]/bottle

B-1

 

EXHIBIT C

Adverse Event Reporting Procedures

ADVERSE EVENT PROCEDURES

These procedures are intended to satisfy regulatory requirements for standard written procedures
for Adverse Event (AE) reporting and for the establishment of explicit procedures and detailed
agreements with commercial partners with respect to compliance with AE Reporting Requirements for
the Product. These procedures may be amended by the parties at any time, by mutual written
agreement, to ensure that they comply with applicable laws and regulations in the countries in
which the Product is marketed. These procedures shall not be construed to restrict Purchaser’s
ability to take action that it deems to be appropriate or required of it under applicable law or
regulations.

The parties’ drug safety groups will discuss and agree to any necessary changes or additions to the
arrangements below.

Definitions:

Definitions are in accordance with FDA guidelines.

Source Document — For reports taken by phone, the documentation made at the time the information
is collected; for written reports, the documentation completed by the reporter or designee. For
both, it includes any additional material pertaining to the report obtained subsequently.

Procedures/Regulatory Responsibilities:

Seller has obligations for processing and reporting adverse events to the relevant regulatory
authorities, including reporting of expedited adverse event reports. In addition, Seller has
obligations for the preparation and submission of periodic reports to FDA. Responsibility for
evaluation of adverse events and signal detection are to be with Seller.

Seller will provide a copy of the periodic report for the Product to Purchaser.

Individual Adverse Events:

     Purchaser shall notify Seller by facsimile or overnight mail within such time of first
learning of an adverse event so as to allow Seller to comply with all reporting requirements
pursuant to law. Where the notification is made via facsimile, Seller shall confirm receipt by
return fax to Purchaser. If an acknowledgment of the adverse event report is not received from
Seller, the report will be re-sent within 48 hours, and marked as re-sent.

     Purchaser will forward all original source documents relating to such adverse events to Seller via
overnight mail.

     Seller retains responsibility for assessing seriousness and expectedness of the adverse event.

C-1

 

Seller is responsible for any additional follow-up regarding the adverse event. If, however,
Purchaser receives additional information regarding the adverse event, the information will be
forwarded to Seller as per the above timeframes.

Seller has responsibility for evaluating adverse events to determine the need for a quality
investigation.

Contact Information:

Seller contact information (to be updated as necessary):

Savient Pharmaceuticals, Inc.

ATTN: Medical Director/ Adverse Event Reports

One Tower Center

Fourteen Floor

East Brunswick, New Jersey 08816

Phone: 732-418-4756

Facsimile: 732-418-9417

Purchaser’s contact information (to be updated as necessary):

Watson Laboratories, Inc.

ATTN: Drug Safety — Adverse Events

311 Bonnie Circle

Corona, CA 92880

Facsimile: (951) 493-5825 or (951) 493-5815

Phone: (951) 493-4399

SOPs and Training:

Both companies will have SOPs relating to the handling of adverse events, specifically, with regard
to each company’s respective responsibilities as per this agreement. Personnel handling adverse
events will be appropriately trained.

C-2

 

EXHIBIT D

Initial Purchase Order Forecast

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	Prior to	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Str.	 	Size	 	 	Launch	 	 	M1	 	M2	 	M3	 	 	M4	 	M5	 	M6	 	 	M7	 	M8	 	M9	 	 	M10	 	M11	 	M12
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[**]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Forecast
	 	 	 	 	 	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]
	WATSON (Sales)
	 	 	 	 	 	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]
	Savient (Supply)
	 	[**]	 	[**]	 	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]
	Inventory Level
	 	 	 	 	 	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]
	Weeks in DC
Inventory
	 	 	 	 	 	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[**]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Forecast
	 	 	 	 	 	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]
	WATSON (Sales)
	 	 	 	 	 	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]
	Savient (Supply)
	 	[**]	 	[**]	 	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]
	Inventory Level
	 	 	 	 	 	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]
	Weeks in DC
Inventory
	 	 	 	 	 	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	M13	 	M14	 	M15	 	 	M16	 	M17	 	M18	 	 	M19	 	M20	 	M21	 	 	M22	 	M23	 	M24	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[**]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Forecast
	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	 	[**]	 
	WATSON (Sales)
	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	 	[**]	 
	Savient (Supply)
	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	 	[**]	 
	Inventory Level
	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	 	[**]	 
	Weeks in DC
Inventory
	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	 	[**]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[**]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Forecast
	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	 	[**]	 
	WATSON (Sales)
	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	 	[**]	 
	Savient (Supply)
	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	 	[**]	 
	Inventory Level
	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	 	[**]	 
	Weeks in DC
Inventory
	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	[**]	 	 	[**]	 	[**]	 	 	[**]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 

D-1

 

EXHIBIT E

Quality Requirements

1.0 QUALITY REQUIREMENTS & DEFINITION

These Quality Requirements define the operating procedures to be followed when Products are
manufactured for Purchaser, either at Seller’s facility or a designated third party manufacturer,
to ensure compliance with cGMPs and other regulatory requirements. Seller will use Commercially
Reasonable Efforts to assure compliance of the contract manufacturer to these requirements. In the
event of conflict between the terms and conditions of this Exhibit and the terms and conditions of
the Agreement, the terms and conditions of the Agreement shall prevail.

1.1 Definition

Terms not defined shall have the meanings set forth in the Agreement including Section 1 thereof.

“Critical Defect” shall mean problems in plant, systems or materials which can affect the quality,
safety, purity or efficacy of products or can lead to health threatening conditions in finished
pharmaceutical products.

2.0 PRODUCT

The Product covered by these Quality Requirements is specified in Exhibit A of the Agreement.

3.0 MANUFACTURE

3.1 Premises

          3.1.1 The premises and equipment used for manufacture must be in compliance with cGMPs,
current regulatory requirements, and in accordance with the documentation approved by the FDA.

3.2 GMP Regulations

The GMPs regulations to be applied are the United States GMPs listed in Title 21 Code of Federal
Regulations (“CFR”) Parts 210 and 211 and associated Compliance Guidances.

3.3 Materials

          3.3.1 Materials Procured by Seller. Seller is responsible for ensuring that all materials
procured for use in the Products are in full compliance with the registered specifications.

3.4 Manufacturing/Packaging/Labeling Documentation

          3.4.1 As referred to in accordance with Section 10 of the Agreement.

E-5

 

          3.4.2 In addition, Seller will maintain original manufacturing and packaging documentation
according to record retention procedure consistent with the FDA requirements.

3.5 Methods

          3.5.1 The Products must be manufactured as specified in the approved NDA. Seller shall
advise Purchaser of any material changes to the manufacturing specifications contained in the
approved NDA within a reasonable amount of time after becoming aware that any such material changes
are required pursuant to any applicable law, rule or regulation.

3.6 Batch Numbering. Seller’s batch numbering system will be used for numbering each batch of each
of the Products made for sale in the Territory. This identification will appear on all documents
relating to the particular batch of the Products. To the extent commercially practicable, the code
for batch numbering identification will be supplied to Purchaser.

3.7 Expiration Dating. The expiration date shall be established from stability data for the
Products. Seller will allocate the Date of Manufacture in accordance with Seller’s internal
procedures.

3.8 Reworking. Any reworking of the Products shall not be permitted without the consent of
Purchaser, such consent not to be unreasonably withheld.

3.9 Manufacturing and Equipment Data. Seller is responsible for keeping records of equipment
usage, raw materials batch numbers and certification, in process results and parameters, and
previous Products used in equipment if non-dedicated equipment is used.

4.0 QUALITY ASSURANCE

4.1 Testing

          4.1.1 Raw materials and packaging components. Seller will ensure that all materials and
components used are in compliance according to the approved NDA.

          4.1.2 In-process testing. Seller is responsible for ensuring that all required in-process
testing is carried out and documented.

          4.1.3 Finished Product. Seller will test all batches of each of the Products to the Product
Specifications and methods according to the approved NDA.

4.2 Release Procedures

          4.2.1 Finished Products. Seller is responsible for ensuring and certifying that the Products
has been made in accordance with the applicable NDA by reviewing all manufacturing and control
information.

          4.2.2 Certificate of Analysis and Certificate of Compliance. Seller will produce a
Certificate of Analysis (C of A) confirming that the Products have been tested, and meet the
registered specifications. Test specifications and test results must be included for each

E-6

 

test in accordance with Exhibit A of the Agreement. Seller will also provide a Certificate of
Compliance (C of C) stating the Products has been manufactured in accordance with the approved
batch record and list all deviations and investigations related to the lot. The C of A and C of C
may be combined into a single document provided all required information is contained therein.
This document shall accompany each batch shipped from Seller.

          4.2.3 Products Acceptance. Purchaser will inspect each delivery of Products from Seller prior
to Purchaser’s release for distribution. Purchaser will notify Seller in writing of any defects.
Purchaser transfer of Products into inventory shall deem Products acceptance by Purchaser.

          4.2.4 Release to the Market. The Quality Assurance Department of Purchaser will release the
Products for distribution on the document package provided by Seller and Purchaser’s product
release procedures.

4.3 Products Refusal

          4.3.1 As referred to in Section 9 of the Agreement.

4.4 Documentation

          4.4.1 Validation batches. Seller is responsible for generating a validation package that
includes: (1) the validation protocol, (2) full batch document packages, (3) all validation data
and (4) validation report for all Validation batches of the Products manufactured. In the event of
a “For Cause Incident,” following prior written request, Purchaser shall have the right to review
the protocols and reports at Seller’s premises during business hours.

          4.4.2 Requests for full documentation. Seller commits to providing a full document package
within three (3) business days if requested by Purchaser for any of the Products where such request
relates to substantiated and reasonable quality concerns, any regulatory reasons (e.g., batch
recall) or audit report which discloses a material defect in the Product.

4.5 Retained Samples

          4.5.1 Raw Materials. Seller will retain sufficient samples of the raw materials, active
materials and excipients used in the manufacture of the Product in accordance with cGMP
regulations.

          4.5.2 Finished Product. Seller will retain, at minimum, sufficient samples of the Products,
to carry out such tests as are required by cGMP regulations.

4.6 Stability

          4.6.1 Seller is responsible for maintaining a stability-testing program for the Products and
will provide a stability report to Purchaser annually. Any problem, which arises as a result of
this program once confirmed, will be promptly notified to Purchaser’s Quality Assurance. A minimum
of one batch per year of the Products shall be included in the Seller

E-7

 

stability program. The parties specifically agree that Seller may utilize stability data
generated from the branded version of the Products and that such data shall be accepted by
Purchaser for the purposes contemplated herein.

          4.6.2 In the event the Agreement is terminated, Seller will continue to generate stability
data to support the acceptability of the Product until all Product distributed by Purchaser has
reached the end of its shelf-life.

4.7 Regulatory Inspections

          4.7.1 In addition to the inspection rights and co-operative efforts contemplated within the
Agreement, Seller will inform Purchaser of any Regulatory Inspections which involve the Products in
accordance with Section 10 of the Agreement.

4.8 Audit

          4.8.1 To be conducted in accordance with Sections 10.3 and 10.4 of the Agreement

4.9 Corrective Actions from Audits

          4.9.1 Critical defects (Substantial GMPs deficiency). In the event any Critical Defects are
observed during audits by Purchaser or regulatory authorities, no further deliveries of Products
may be delivered to Purchaser until corrective actions have been completed to Purchaser’s
satisfaction, as reasonably determined by Purchaser.

          4.9.2 Other defects. In the case of other defects (minor cGMPs issues) observed during audits
by Purchaser or regulatory authorities, a reasonably satisfactory corrective action program must be
in place. Purchaser shall reasonably agree with the program before further deliveries of Products
to Purchaser may be made; however, approval of any corrective action or corrective action program
by a regulatory authority with jurisdiction shall be conclusive evidence as to such corrective
action/program’s acceptability.

4.10 Recalls/Product Complaints/Field Alerts

          4.10.1 Recalls. Seller is responsible to notify Purchaser promptly of any issues that could
result in a Recall in accordance with Section 10.5 of the Agreement.

          4.10.2 Product Complaints. Purchaser will forward the complaint to Seller within five (5)
calendar days from the date received by Purchaser’s Corporate Quality Complaint Operations. Seller
will initiate an investigation according to its standard operating procedures. A written report of
the investigation shall be sent to Purchaser Corporate Compliant operation within thirty (30)
calendar days of the resolution of the forwarded complaint. Purchaser shall respond directly to all
complainants. Should either party receive follow-up information from a complainant with respect to
an ongoing or previous complaint investigation such information will be promptly reported to the
other party.

E-8

 

          4.10.3 Field Alerts. Product issues arising from stability data or other manufacturing issues
that meet Field Alert Report criteria, once confirmation is received that such criteria is met,
will be promptly communicated to Purchaser. Purchaser and Seller will jointly evaluate and prepare
reports for filing by Seller, as required by law.

4.11 Change Control and Deviations

          4.11.1 Change Control. Seller will comply with cGMPs in its change control procedures. Seller
shall notify Purchaser in writing of any material change to source of Active Pharmaceutical
Ingredient, equipment used in manufacturing, primary packaging material, Product Specifications,
manufacturing process, or any other change that affects the registration status. Seller shall
assure Purchaser of supply of the Products during such time as may be required to amend its NDA for
such changes.

          4.11.2 Deviations. Seller will record any unplanned deviations from the manufacturing process
and/or testing of the Products in the batch/testing records and clearly notify Purchaser in writing
of any and all deviations from the Quality Requirements for each batch; the notifications
contemplated herein may be provided in the form of the Certificate of Compliance.

4.12 Failures Investigation

          4.12.1 Seller is responsible for investigating any test result or in-process test that fails
to meet specification. Where appropriate, each investigation must give rise to a corrective
action, which must be reviewed and approved by Seller.

          4.12.2 If the recommendation is to release the batch which is the subject of such
investigation as-is, the investigation must document that any failure has not jeopardized the
safety, efficacy or quality of the Products. To support this assurance, additional sampling,
testing and checks may be required and these must be recorded in the batch file.

4.13 Annual Product Review

          4.13.1 Seller is responsible for preparing the Annual Product Review (APR) for the Products
manufactured. Purchaser, as the marketer of the Products, will provide any and all information to
Seller that is required of the marketer for the compilation of the APR. A copy of the report shall
be provided to Purchaser.

5.0 VALIDATION

5.1 Process

Seller is responsible for ensuring that the manufacturing process for the Products is validated
before any routine production can start. The validation should ensure that the process is capable
of consistently meeting the Products Specifications. In the event of a “For Cause Incident,”
Seller shall make validation protocols and reports available for review by Purchaser upon prior
written request at Seller’s premises during business hours.

E-9

 

5.2 Cleaning

Seller is responsible for ensuring that a validated equipment cleaning method is used and adequate
cleaning is carried out for each batch of manufactured Product. Purchaser shall review the
cleaning validation on an audit basis.

5.3 Computer System

Seller is responsible for ensuring that computer systems which are used for the manufacturing
process and/or laboratory testing of the batch must be validated. Validation protocols and reports
shall be available for Purchaser for review during an audit.

6.0 STORAGE AND SHIPPING

Seller will ensure that during packaging, storage and shipment of the Products that there is no
possibility of deterioration, contamination or admixture with any other materials. Seller will only
ship goods to Purchaser’s designated locations.

E-10

 

Appendix I to Exhibit E

Certificate of Analysis

[**]

E-11

 

EXHIBIT F

Form of Press Release

Savient
Pharmaceuticals, Inc.
(“Savient” or“the Company”) announced
today that Watson Pharmaceuticals, under the terms of its previous
supply and distribution agreement with Savient, has launched an
authorized generic of oxandrolone tablets,
USP (C-III), an Oxandrin® brand equivalent product
manufactured and supplied through Savient. The authorized generic
product will be launched immediately and distributed by Watson in
both the 2.5 mg and 10 mg dosages.
The authorized generic of oxandrolone tablets
will continue to meet all quality control standards of the
Oxandrin® brand and will contain the same active and inactive
pharmaceutical ingredients. Oxandrin® is Savient’s oral
anabolic agent for the treatment of involuntary weight loss, a
frequent and sometimes life-threatening condition associated with
numerous disease states. Savient will continue to market and
distribute the Oxandrin® brand product.

E-12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]